WO2015099187A1 - 遺伝子発現制御のための人工マッチ型miRNAおよびその用途 - Google Patents
遺伝子発現制御のための人工マッチ型miRNAおよびその用途 Download PDFInfo
- Publication number
- WO2015099187A1 WO2015099187A1 PCT/JP2014/084724 JP2014084724W WO2015099187A1 WO 2015099187 A1 WO2015099187 A1 WO 2015099187A1 JP 2014084724 W JP2014084724 W JP 2014084724W WO 2015099187 A1 WO2015099187 A1 WO 2015099187A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- artificial match
- type mirna
- region
- chemical formula
- artificial
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Definitions
- the present invention relates to an artificial match-type miRNA that suppresses gene expression and uses thereof.
- Micro RNA is known as a nucleic acid molecule that suppresses gene expression, and has been reported to suppress transcription of a protein encoded by the gene through, for example, the following generation process. That is, first, a miRNA transcript (Pri-miRNA) having a cap structure at the 5 'end and poly (A) at the 3' end is generated in the nucleus. The Pri-miRNA is cleaved by RNase (Drosha) to generate a miRNA precursor (Pre-miRNA). The Pre-miRNA has a hairpin structure having a loop region and a stem region.
- Pri-miRNA miRNA transcript having a cap structure at the 5 'end and poly (A) at the 3' end is generated in the nucleus.
- the Pri-miRNA is cleaved by RNase (Drosha) to generate a miRNA precursor (Pre-miRNA).
- the Pre-miRNA has a hairpin structure having a loop region and a stem region.
- This Pre-miRNA moves out of the nucleus, and then is degraded by cytoplasmic RNase (Dicer) to cut out double-stranded miRNA (mature miRNA) having a 1 to 4 base overhang at the 3 'end.
- double-stranded miRNAs one strand is called a guide strand, the other strand is called a passenger strand, and the guide strand binds to a complex similar to RNA-induced Silencing Complex (RISC).
- RISC RNA-induced Silencing Complex
- the miRNA / RISC complex binds to the 3 'untranslated region (3'UTR) of a specific mRNA, thereby suppressing protein translation from the mRNA.
- the miRNA for example, there is a method using a double-stranded mature miRNA.
- this method requires the annealing of two single-stranded nucleic acid molecules prior to use, and may generate autoimmunity by TLR3 or the like that recognizes the double strand.
- an object of the present invention is to provide a new artificial match-type miRNA using miRNA.
- the artificial match-type miRNA of the present invention comprises: A single-stranded nucleic acid having an X region and a Y region, The 3 ′ end of the X region and the 5 ′ end of the Y region are linked via a linker region having a non-nucleotide structure,
- the X region includes a guide strand sequence of a mature miRNA;
- the Y region includes a sequence completely complementary to the X region.
- composition of the present invention is a composition for suppressing gene expression, and includes the artificial match-type miRNA of the present invention.
- composition of the present invention is a pharmaceutical composition, characterized in that it contains the artificial match-type miRNA of the present invention.
- the expression suppression method of the present invention is a method of suppressing the expression of a target gene, characterized by using the artificial match-type miRNA of the present invention.
- the method for treating a disease of the present invention includes a step of administering the artificial match-type miRNA of the present invention to a patient, and the guide strand sequence in the artificial match-type miRNA suppresses the expression of a gene involved in the disease. It is a guide strand sequence of mature miRNA.
- the artificial match-type miRNA of the present invention can be easily synthesized at low cost, and can suppress the translation of the protein encoded by the gene.
- FIG. 1 is a schematic view showing an example of the artificial match-type miRNA of the present invention.
- FIG. 2 is a graph showing the number of cells per well in Example 1 of the present invention.
- FIG. 3 is a graph showing the relative values of cell proliferation in Example 1 of the present invention.
- FIG. 4 is a graph showing the percentage of apoptosis in Example 1 of the present invention.
- FIG. 5 is a graph showing the relative values of the amount of AXL mRNA and the amount of MET mRNA in Example 1 of the present invention.
- FIG. 6 is a graph showing the relative value of the amount of AXL mRNA in Example 2 of the present invention.
- FIG. 7 is a graph showing the relative value of the amount of MET mRNA in Example 2 of the present invention.
- FIG. 8 is a graph showing the relative value of the amount of AXL mRNA in Example 3 of the present invention.
- FIG. 9 is a graph showing the relative value of the amount of MET mRNA in Example 3 of the present invention.
- FIG. 10 is a graph showing the relative value of the amount of HMGA2 mRNA in Example 4 of the present invention.
- FIG. 11 is a graph showing the relative value of the amount of COLA1 mRNA in Example 5 of the present invention.
- the artificial match-type miRNA of the present invention as described above, A single-stranded nucleic acid having an X region and a Y region, The 3 ′ end of the X region and the 5 ′ end of the Y region are linked via a linker region having a non-nucleotide structure,
- the X region includes a guide strand sequence of a mature miRNA;
- the Y region includes a sequence completely complementary to the X region.
- the artificial match-type miRNA of the present invention can suppress the expression of a target gene, for example.
- Expression suppression means, for example, suppression of translation of the target gene, that is, suppression of translation of a protein encoded by the target gene, and more specifically, suppression of translation of the protein from mRNA of the target gene.
- the suppression of the expression of the target gene can be achieved, for example, by reducing the production amount of the transcription product from the target gene, reducing the activity of the transcription product, reducing the production amount of the translation product from the target gene, or activity of the translation product. It can be confirmed by decrease of Examples of the protein include a mature protein or a precursor protein before undergoing processing or post-translational modification.
- the artificial match-type miRNA of the present invention is a single-stranded nucleic acid molecule, for example, it is not necessary to anneal two single-strands like mature miRNA, and can be produced at low cost. Furthermore, since the artificial match-type miRNA of the present invention is a single-stranded nucleic acid molecule, it can be prevented from being recognized by, for example, TLR3, RIG-I, MDA5, etc. involved in autoimmunity.
- FIG. 1 shows an outline of the positional relationship between the X region and the Y region in the artificial match-type miRNA of the present invention.
- FIG. 1 is schematic, and for example, the length, shape, and the like of each region are not limited.
- the artificial match-type miRNA of the present invention has the X region disposed on the 5 ′ side, the Y region disposed on the 3 ′ side, and the 3 ′ end of the X region and the Y region.
- the 5 ′ end is linked via a non-nucleotide structure linker region (indicated by “P” in the figure).
- the Y region includes a sequence that is completely complementary to the X region
- the X region and the Y region are annealed intramolecularly, for example.
- Intramolecular annealing is also referred to as self-annealing, for example.
- the artificial match-type miRNA of the present invention is also said to form a double strand in the intramolecularly annealed region.
- the artificial match-type miRNA of the present invention can also be referred to as a linear single-stranded nucleic acid molecule in which the 5 'end and 3' end are not linked.
- the artificial match-type miRNA of the present invention preferably has a non-phosphate group at the 5 'end, for example, to maintain unbonded both ends.
- the X region includes a guide strand sequence of mature miRNA as described above.
- the guide strand sequence of mature miRNA is registered in various databases (for example, http://www.mirbase.org/ etc.). Therefore, for example, the X region can be set based on information of these known mature miRNAs.
- the guide strand of the mature miRNA is a strand that is incorporated into the RNA-induced silencing complex (RISC) Argonaute (Ago) protein and binds to the target mRNA.
- RISC RNA-induced silencing complex
- the X region may consist of, for example, only the guide strand sequence or may have an additional sequence.
- the X region is composed of, for example, the guide strand sequence and the additional sequence, and the additional sequence is linked to the 3 ′ end of the guide strand sequence, for example.
- the Y region includes a sequence that is completely complementary to the X region when the X region and the Y region are aligned.
- the Y region may consist of, for example, a sequence that is completely complementary to the X region, or may have an overhang in addition to the complementary sequence. That is, in the artificial match-type miRNA of the present invention, for example, when the Y region and the X region are aligned, the Y region may have an overhang at the 3 ′ end.
- the overhang of the Y region is, for example, a terminal base that the Y region has more than the X region when the Y region and the X region are aligned.
- the length of each region is not particularly limited.
- the conditions are exemplified below, but the artificial match-type miRNA of the present invention is not limited to these descriptions.
- the numerical range of bases discloses all positive integers belonging to the range.
- the description “1 to 4 bases” means “1, 2, 3, 4 bases”. (Hereinafter the same).
- the length of the guide strand sequence is not particularly limited, and for example, the length of the guide strand sequence in the reported mature miRNA can be exemplified.
- the lower limit is, for example, 19 base lengths and 20 base lengths
- the upper limit is, for example, 25 base lengths, 24 base lengths
- the range is, for example, 19-25 base lengths, 20-24 base lengths It is.
- the length of the additional sequence in the X region is not particularly limited, and the lower limit is, for example, 0 base length, 1 base length, 2 base length, and the upper limit is, for example, 5 base length, 4 base length, 3
- the base length is, for example, 0 to 5 bases, 1 to 5 bases, 1 to 4 bases, 2 to 3 bases, 3 to 5 bases.
- the length of the X region is not particularly limited, and the lower limit is, for example, 19 base length, 21 base length, 23 base length, and the upper limit is, for example, 30 base length, 28 base length, 26 base length.
- the range is, for example, 19-30 bases long, 21-28 bases long, 23-26 bases long.
- the length of the overhang in the Y region is not particularly limited, and the lower limit is, for example, 0 base length, 1 base length, the upper limit is, for example, 4 base length, 3 base length, and the range is For example, it is 0 to 4 bases long, 1 to 3 bases long, 2 bases long.
- the arrangement of the overhang is not particularly limited, and examples thereof include UU, CU, GC, UA, AA, CC, UG, CG, AU, and TT from the 3 'side.
- the overhang is TT, resistance to RNase can be added.
- the length of the Y region is not particularly limited, and the lower limit is, for example, 19 base length, 21 base length, 23 base length, and the upper limit is, for example, 32 base length, 30 base length, 28 base length.
- the range is, for example, 19 to 32 bases long, 21 to 30 bases long, 23 to 28 bases long.
- the total length (T) of the artificial match-type miRNA of the present invention is not particularly limited, and the lower limit is, for example, 38 base length, 42 base length, 46 base length, and the upper limit is, for example, 62 base length, 58 base length. 54 base length, and the range is, for example, 38 to 62 base length, 42 to 58 base length, 46 to 54 base length.
- the type of the mature miRNA is not particularly limited, and can be appropriately selected according to the type of the target gene.
- Examples of the mature miRNA include hsa-miR-34a (SEQ ID NO: 1), hsa-let-7a (SEQ ID NO: 2), hsa-let-7f (SEQ ID NO: 3), and hsa-miR-150 (SEQ ID NO: 4). ), Mature miRNA such as hsa-miR-29b (SEQ ID NO: 5).
- hsa-miR-34a SEQ ID NO: 1
- UGGCAGUGUCUUAGCUGGUUGU hsa-let-7a SEQ ID NO: 2
- UGAGGUAGUAGGUUGUAUAGUU hsa-let-7f SEQ ID NO: 3
- UGAGGUAGUAGAUUGUAUAGUU hsa-miR-150 SEQ ID NO: 4
- UCUCCCAACCCUUGUACCAGUG hsa-miR-29b SEQ ID NO: 5
- UAGCACCAUUUGAAAUCAGUGUU the nucleotide sequence represented by each SEQ ID NO represents a guide strand sequence.
- the guide chain of miR-34a targets, for example, AXL, MET, CDK4, CDK6, SIRT1, CCND1, SIRT1, BCL-2, etc., and suppresses the expression of these target genes, for example, lung cancer, colon cancer, gastric cancer It can prevent or treat diseases such as liver cancer and breast cancer.
- the guide strand of let-7a targets, for example, HMGA2 (high mobility group AT-hook 2), KRAS, NRAS, HRAS, MYC, TLR4 and the like, and by suppressing the expression of these target genes, for example, lung cancer and colon Can prevent or treat diseases such as cancer, stomach cancer, liver cancer and breast cancer.
- the guide strand of let-7f targets, for example, HMGA2 (high mobility group AT-hook 2), KRAS, NRAS, HRAS, MYC, TLR4, etc., and by suppressing the expression of these target genes, for example, lung cancer and colon Can prevent or treat diseases such as cancer, stomach cancer, liver cancer and breast cancer.
- the guide chain of miR-29b targets, for example, COL1A1, MCL1, DNMT3A, DNMT3B, TCL1A, TGFb3, etc., and suppresses the expression of these target genes, for example, lung cancer, colon cancer, stomach cancer, liver cancer, breast cancer Diseases such as pulmonary fibrosis and liver fibrosis can be prevented or treated.
- the structural unit of the artificial match-type miRNA of the present invention is not particularly limited, and examples thereof include nucleotide residues.
- the nucleotide residue include a ribonucleotide residue and a deoxyribonucleotide residue.
- the nucleotide residue is preferably, for example, a ribonucleotide residue.
- the nucleotide residue include an unmodified unmodified nucleotide residue and a modified modified nucleotide residue.
- the artificial match-type miRNA of the present invention can improve nuclease resistance and stability, for example, by including the modified nucleotide residue.
- the artificial match-type miRNA of the present invention may further include a non-nucleotide residue in addition to the nucleotide residue, for example.
- the number of the modified ribonucleotide residue is not particularly limited.
- “1 Specifically, the number is, for example, 1 to 5, preferably 1 to 4, more preferably 1 to 3, and most preferably 1 or 2.
- the modified ribonucleotide residue relative to the unmodified ribonucleotide residue may be, for example, the deoxyribonucleotide residue in which a ribose residue is replaced with a deoxyribose residue.
- the artificial match-type miRNA of the present invention includes, for example, the deoxyribonucleotide residue in addition to the unmodified ribonucleotide residue
- the number of the deoxyribonucleotide residue is not particularly limited. Specifically, for example, 1 to 5, preferably 1 to 4, more preferably 1 to 3, and most preferably 1 or 2.
- the nucleotide residue includes, for example, a sugar, a base and a phosphate as constituent elements.
- the ribonucleotide residue has, for example, a ribose residue as a sugar, and has adenine (A), guanine (G), cytosine (C) and U (uracil) as bases
- the deoxyribose residue is For example, it has a deoxyribose residue as a sugar and has adenine (A), guanine (G), cytosine (C) and thymine (T) as bases.
- each component is the same or substantially the same as, for example, naturally occurring, specifically, for example, the same or substantially the same as that naturally occurring in the human body. Are identical.
- the modified nucleotide residue may be modified, for example, with any component of the unmodified nucleotide residue.
- Examples of the modified nucleotide residue include naturally occurring nucleotide residues, artificially modified nucleotide residues, and the like.
- the modified nucleotide residue may be, for example, a residue of a substitute for the unmodified nucleotide.
- the substitute include artificial nucleic acid monomer residues. Specific examples include PNA (peptide nucleic acid), LNA (Locked Nucleic Acid), ENA (2'-O, 4'-C-Ethylenebridged Nucleic Acid), and the like.
- the base is not particularly limited.
- the base may be, for example, a natural base or a non-natural base.
- the base may be, for example, naturally derived or a synthetic product.
- As the base for example, a general base or a modified analog thereof can be used.
- the linker region having the non-nucleotide structure preferably includes at least one selected from the group consisting of amino acid residues, polyamine residues, and polycarboxylic acid residues.
- the linker region may or may not contain residues other than amino acid residues, polyamine residues, and polycarboxylic acid residues.
- the linker region may include any of a polycarboxylic acid residue, a terephthalic acid residue, or an amino acid residue.
- polyamine refers to any compound containing a plurality (two or three or more) amino groups.
- the “amino group” is not limited to —NH 2 group but also includes imino group (—NH—).
- the polyamine is not particularly limited, and examples thereof include 1,4-diaminobenzene, 1,3-diaminobenzene, 1,2-diaminobenzene and the like.
- polycarboxylic acid refers to any compound containing a plurality (two or three or more) of carboxy groups. In the present invention, the polycarboxylic acid is not particularly limited.
- amino acid refers to any organic compound containing one or more amino groups and carboxy groups in the molecule, as will be described later.
- amino group is not limited to —NH 2 group but also includes imino group (—NH—).
- the amino acid residue may be a combination of a plurality of amino acid residues.
- an amino acid residue in which a plurality of amino acid residues are linked refers to, for example, a residue containing a peptide structure. More specifically, the amino acid residue in which the plurality of amino acid residues are linked is, for example, an amino acid residue represented by chemical formula (I) described later, wherein a chemical formula (Ia) described later is a peptide (for example, glycine dimer or An amino acid residue that is a glycine trimer or the like.
- the amino acid residue may be a glycine residue, a terephthalic acid amide residue, a proline residue, or a lysine residue.
- the amino acid residue may be a modified amino acid residue or an amino acid derivative.
- the linker region is represented, for example, by the following chemical formula (I-0).
- Q11 and Q12 are each independently a single bond, CH 2 (methylene group), NH (imino group), C ⁇ O (carbonyl group), C ⁇ S (thiocarbonyl group), C ⁇ NH (iminomethylene group) ), O, or S
- Q1 and Q2 are each independently a single bond, CH 2 (methylene group), NH (imino group), C ⁇ O (carbonyl group), C ⁇ S (thiocarbonyl group), C ⁇ NH (iminomethylene group) ), O, or S
- Y 1 and Y 2 are each independently a single bond, CH 2 , NH, O or S
- L 1 is an alkylene chain having n carbon atoms, and a hydrogen atom on the alkylene carbon atom is substituted with OH, OR a , NH 2 , NHR a , NR a R b , SH, or SR a May not be substituted
- L1 is a polyether chain in which one or more carbon atom
- L 2 is a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom
- Y 2 is NH, O or S
- the atom of L 2 bonded to Y 2 is carbon
- the atom of L 2 bonded to OR 2 is carbon
- oxygen atoms are not adjacent to each other
- R a , R b , R c and R d are each independently a substituent or a protecting group
- m is an integer ranging from 0 to 30
- n is an integer ranging from 0 to 30
- the X region and the Y region are each bonded to the linker residue via —OR 1 — or —OR 2 —;
- R 1 and R 2 may or may not be present, and when present, R 1 and R 2 are each independently a nucleotide residue or the structure (I-0).
- A is an arbitrary atomic group.
- the combination of the bond between the X region and the Y region and —OR 1 — and —OR 2 — is not particularly limited, and examples thereof include any of the following conditions.
- Condition (1) The X region is bonded to the structure of the formula (I) through —OR 2 —, and the Y region is bonded through —OR 1 —.
- Condition (2) The X region is bonded to the structure of the formula (I) through —OR 1 — and the Y region is bonded through —OR 2 —.
- Q 11 may be C ⁇ O (carbonyl group) and Q 1 may be NH (imino group). Further, for example, Q 11 may be NH (imino group) and Q 1 may be C ⁇ O (carbonyl group). Further, for example, Q 12 may be C ⁇ O (carbonyl group) and Q 2 may be NH (imino group). Further, for example, Q 12 may be NH (imino group) and Q 2 may be C ⁇ O (carbonyl group).
- Q 11 and Q 12 may each be, for example, a carbonyl group.
- Q 1 and Q 2 are each preferably an imino group.
- the structure of the following chemical formula (I ⁇ ) is more preferably represented by the following chemical formula (I ⁇ 2).
- R 100 is an arbitrary substituent and may or may not be present. When present, one or a plurality of R 100 may be present, and in the case of a plurality, R 100 may be the same as or different from each other.
- R 100 examples include the substituents described below for R a , R b , R c, and R d , and more specifically, for example, halogen, hydroxy, alkoxy, Amino, carboxy, sulfo, nitro, carbamoyl, sulfamoyl, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl, alkylaryl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cyclylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl Silyl, silyloxyalkyl, pyrrolyl, imidazolyl, and the like. More preferably, the structure of the chemical formula (I ⁇ 2) is represented by the following chemical formula (I ⁇ 3).
- the linker residue of the chemical formula (I-0) is a carboxylic acid amide residue. It can also be said that it is a carboxylic acid residue.
- the “TPA” structure in the examples described later can be said to be a terephthalic acid amide residue, but it can also be said to be a terephthalic acid residue represented by the chemical formula (I ⁇ 3).
- Q 11 and Q 12 may each be an imino group.
- Q 1 and Q 2 are each preferably a carbonyl group.
- the structure represented by the following chemical formula (I ⁇ ) is more preferably represented by the following chemical formula (I ⁇ 2).
- R 100 is an arbitrary substituent and may or may not be present. When present, one or a plurality of R 100 may be present, and in the case of a plurality, R 100 may be the same as or different from each other. Specifically, for example, it is the same as R 100 in the chemical formula (I ⁇ 2). More preferably, the structure of the chemical formula (I ⁇ 2) is represented by the following chemical formula (I ⁇ 3).
- the linker residue is an amino acid residue
- the amino acid residue is represented, for example, by the following chemical formula (I).
- the structure of the following chemical formula (I) is an example of a structure represented by the chemical formula (I-0).
- X 1 , X 2 , Y 1 , Y 2 , L 1 and L 2 are the same as described above.
- the complementary sequence to the sequence of the microRNA binds to the amino acid residue via —OR 1 — or —OR 2 —, respectively.
- R 1 and R 2 may or may not be present, and when present, R 1 and R 2 are each independently a nucleotide residue or the structure (I);
- A is an arbitrary atomic group, provided that the following chemical formula (Ia) is an amino acid or a peptide.
- the atomic group A in the chemical formula (I), (I ⁇ ) or (Ia) is, for example, a chain group, an alicyclic group, an aromatic group, a heteroaromatic group, or a heteroalicyclic group. It may or may not include at least one selected from the group consisting of formula atomic groups.
- the chain atomic group is not particularly limited, and examples thereof include alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, silyl, silyloxyalkyl and the like.
- the alicyclic atomic group is not particularly limited, and examples thereof include cycloalkyl, cycloalkenyl, cycloalkylalkyl, cyclylalkyl and the like.
- the aromatic atomic group is not particularly limited, and examples thereof include aryl, arylalkyl, alkylaryl, condensed ring aryl, condensed ring arylalkyl, and condensed ring alkylaryl.
- the heteroaromatic atomic group is not particularly limited, and examples thereof include heteroaryl, heteroarylalkyl, alkylheteroaryl, fused ring heteroaryl, fused ring heteroarylalkyl, and fused ring alkylheteroaryl. .
- each atomic group may or may not further have a substituent or a protecting group.
- substituents or protecting groups they may be the same or different.
- substituents include the substituents exemplified for the above R a , R b , R c and R d , and more specifically, for example, halogen, hydroxy, alkoxy, amino, carboxy, sulfo, nitro Carbamoyl, sulfamoyl, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl, alkylaryl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cyclylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, silyl, silyloxyalkyl, Examples include pyrrolyl,
- amino acid refers to any organic compound containing at least one amino group and one carboxy group in the molecule, as described above.
- the “amino group” is not limited to —NH 2 group but also includes imino group (—NH—).
- imino group —NH—
- proline, hydroxyproline and the like do not contain an —NH 2 group in the molecule but an imino group (—NH—), and are included in the definition of “amino acid” in the present invention.
- the “amino acid” may be a natural amino acid or an artificial amino acid as described later.
- a compound represented by the following chemical formula (Ia2) or (Ia3) also includes an amino group and a carboxy group in the molecule, and thus is included in the definition of “amino acid” in the present invention. Therefore, for example, in the chemical formula (I), the structure in which the atomic group A is represented by the following chemical formula (A2) or chemical formula (A2a) is included in the definition of “amino acid residue” in the present invention. Further, for example, the “TPA” structure in Examples described later is also included in the definition of “amino acid residue” in the present invention.
- “peptide” refers to an organic compound having a structure in which two or more amino acids are bound by peptide bonds.
- the peptide bond may have an acid amide structure or an acid imide structure.
- the amino group explicitly shown in the chemical formula (Ia) may be any amino group.
- the carboxy group clearly shown in the chemical formula (Ia) may be any carboxy group.
- the amino acid may be a natural amino acid or an artificial amino acid as described above, for example.
- “natural amino acid” refers to an amino acid having a naturally occurring structure or an optical isomer thereof.
- the method for producing the natural amino acid is not particularly limited, and for example, it may be extracted from nature or synthesized.
- “artificial amino acid” refers to an amino acid having a structure that does not exist in nature. That is, the artificial amino acid refers to a carboxylic acid derivative containing an amino acid, that is, an amino group (an organic compound containing one or more amino groups and carboxy groups in the molecule) and having a structure that does not exist in nature.
- the artificial amino acid preferably does not include a heterocycle.
- the amino acid may be, for example, an amino acid constituting a protein.
- the amino acid include glycine, ⁇ -alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, hydroxylysine, methionine, phenylalanine, serine, threonine, tyrosine, valine, At least selected from the group consisting of proline, 4-hydroxyproline, tryptophan, ⁇ -alanine, 1-amino-2-carboxycyclopentane, aminobenzoic acid, aminopyridinecarboxylic acid, and an amino acid represented by the following chemical formula (Ia2)
- substituents examples include the substituents exemplified for Ra, Rb, Rc and Rd, and more specifically, for example, halogen, hydroxy, alkoxy, amino, carboxy, sulfo, nitro, carbamoyl, sulfamoyl.
- Examples of the protecting group are the same as those exemplified for Ra, Rb, Rc and Rd.
- an amino acid that is not a peptide of the chemical formula (Ia) has an isomer such as an optical isomer, a geometric isomer, or a stereoisomer, any isomer may be used.
- R100 is an arbitrary substituent and may or may not be present. If present, one or a plurality of R100 may be present, and in the case of a plurality, they may be the same as or different from each other.
- the optional substituent in R100 include the substituents exemplified for Ra, Rb, Rc and Rd, and more specifically, for example, halogen, hydroxy, alkoxy, amino, carboxy, sulfo, nitro.
- the structure of the chemical formula (Ia) is the chemical formula (Ia2)
- the structure of the atomic group A in the chemical formula (I) is represented by the following chemical formula (A2).
- R100 in the following chemical formula (A2) is the same as R100 in the chemical formula (Ia2).
- the structure of the chemical formula (Ia) is the chemical formula (Ia3)
- the structure of the atomic group A in the chemical formula (I) is represented by the following chemical formula (A2a).
- Examples of the structure of the chemical formula (I) include the following chemical formulas (I-1) to (I-7).
- n and m are the chemical formulas Same as (I).
- n and m are not particularly limited and are as described above.
- the structure is shown in the following chemical formulas (I-1a), (I-1b) (I-4a), (I-6a) and (I-7a).
- the linker region is represented by the following formula (II), for example.
- X 1 and X 2 are each independently H 2 , O, S or NH; Y 1 and Y 2 are each independently a single bond, CH 2 , NH, O or S; R 3 is a hydrogen atom or substituent bonded to C-3, C-4, C-5 or C-6 on ring A; L 1 is an alkylene chain consisting of n atoms, wherein the hydrogen atom on the alkylene carbon atom is replaced with OH, OR a , NH 2 , NHR a , NR a R b , SH, or SR a May or may not be substituted, or L 1 is a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom,
- Y 1 is NH, O or S
- the atom of L 1 bonded to Y 1 is carbon
- the atom of L 1 bonded to OR 1 is carbon, and oxygen atoms are not adjacent to each other
- L 2 is
- the ring A may contain a carbon-carbon double bond or a carbon-nitrogen double bond
- the X region and the Y region are each bonded to the non-nucleotide structure via —OR 1 — or —OR 2 —;
- R 1 and R 2 may or may not be present, and when present, R 1 and R 2 are each independently a nucleotide residue or the structure (II).
- X 1 and X 2 are each independently, for example, H 2 , O, S or NH.
- X 1 being H 2 means that X 1 forms CH 2 (methylene group) together with the carbon atom to which X 1 is bonded. The same is true for X 2.
- Y 1 and Y 2 are each independently a single bond, CH 2 , NH, O or S.
- l 1 or 2.
- ring A is a 5-membered ring, for example, the pyrrolidine skeleton.
- the pyrrolidine skeleton include a proline skeleton and a prolinol skeleton, and examples thereof include a bivalent structure.
- ring A is a 6-membered ring, for example, the piperidine skeleton.
- one carbon atom other than C-2 on ring A may be substituted with nitrogen, oxygen or sulfur.
- Ring A may contain a carbon-carbon double bond or a carbon-nitrogen double bond in ring A.
- Ring A may be, for example, either L-type or D-type.
- R 3 is a hydrogen atom or a substituent bonded to C-3, C-4, C-5 or C-6 on the ring A.
- R 3 is the above-described substituent, the substituent R 3 may be one, plural, or absent, and when plural, it may be the same or different.
- the substituent R 3 is, for example, halogen, OH, OR 4 , NH 2 , NHR 4 , NR 4 R 5 , SH, SR 4 or an oxo group ( ⁇ O).
- R 4 and R 5 are, for example, each independently a substituent or a protecting group, and may be the same or different.
- substituents include halogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cyclylalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, heterocyclylalkenyl. , Heterocyclylalkyl, heteroarylalkyl, silyl, silyloxyalkyl and the like. The same applies hereinafter.
- the substituent R 3 may be any of these listed substituents.
- the protecting group is, for example, a functional group that converts a highly reactive functional group to inert, and examples thereof include known protecting groups.
- the description of the literature J. F. W. McOmie, “Protecting Groups in Organic Chemistry” Prenum Press, London and New York, 1973) can be used as the protecting group.
- the protective group is not particularly limited, and examples thereof include tert-butyldimethylsilyl group (TBDMS), bis (2-acetoxyethyloxy) methyl group (ACE), triisopropylsilyloxymethyl group (TOM), 1- (2 -Cyanoethoxy) ethyl group (CEE), 2-cyanoethoxymethyl group (CEM), tolylsulfonylethoxymethyl group (TEM), dimethoxytrityl group (DMTr) and the like.
- TBDMS tert-butyldimethylsilyl group
- ACE (2-acetoxyethyloxy) methyl group
- TOM triisopropylsilyloxymethyl group
- CEE 2-Cyanoethoxymethyl group
- CEM 2-cyanoethoxymethyl group
- TEM dimethoxytrityl group
- DMTr dimethoxytrityl group
- R 3 is OR 4
- the protecting group is not particularly
- L 1 is an alkylene chain composed of n atoms.
- the hydrogen atom on the alkylene carbon atom may be substituted with, for example, OH, OR a , NH 2 , NHR a , NR a R b , SH, or SR a , or may not be substituted.
- L 1 may be a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom.
- the polyether chain is, for example, polyethylene glycol.
- L 2 is an alkylene chain composed of m atoms.
- the hydrogen atom on the alkylene carbon atom may be substituted with, for example, OH, OR c , NH 2 , NHR c , NR c R d , SH or SR c , or may not be substituted.
- L 2 may be a polyether chain in which one or more carbon atoms of the alkylene chain are substituted with an oxygen atom.
- Y 2 is NH, O or S
- the L 2 atom bonded to Y 2 is carbon
- the L 2 atom bonded to OR 2 is carbon
- oxygen atoms are not adjacent to each other. That is, for example, when Y 2 is O, the oxygen atom and the oxygen atom of L 2 are not adjacent, and the oxygen atom of OR 2 and the oxygen atom of L 2 are not adjacent.
- N in L 1 and m in L 2 are not particularly limited, and the lower limit is, for example, 0, and the upper limit is not particularly limited.
- n and m can be appropriately set according to the desired length of the non-nucleotide structure, for example.
- n and m are each preferably 0 to 30, more preferably 0 to 20, and still more preferably 0 to 15 from the viewpoint of production cost and yield.
- n + m is, for example, 0 to 30, preferably 0 to 20, and more preferably 0 to 15.
- R a , R b , R c and R d are, for example, each independently a substituent or a protecting group.
- the substituent and the protecting group are the same as described above, for example.
- hydrogen atoms may be independently substituted with halogens such as Cl, Br, F and I, for example.
- the X region and the Y region are bonded to the non-nucleotide structure via, for example, —OR 1 — or —OR 2 —, respectively.
- R 1 and R 2 may or may not exist.
- R 1 and R 2 are each independently a nucleotide residue or the structure of formula (II).
- the non-nucleotide structure is, for example, the non-nucleotide residue having the structure of the formula (II) excluding the nucleotide residue R 1 and / or R 2 , And the nucleotide residues.
- the non-nucleotide structure is, for example, a structure in which two or more of the non-nucleotide residues having the structure of the formula (II) are linked. Become.
- the structure of formula (II) may include, for example, 1, 2, 3 or 4.
- the structure (II) may be directly linked or may be bonded via the nucleotide residue.
- R 1 and R 2 are not present, the non-nucleotide structure is formed only from the non-nucleotide residue consisting of the structure of the formula (II), for example.
- the combination of the bond between the X region and the Y region and —OR 1 — and —OR 2 — is not particularly limited, and examples thereof include any of the following conditions.
- Condition (1) The X region is bonded to the structure of the formula (II) through —OR 2 — and the Y region is bonded through —OR 1 —.
- Condition (2) The X region is bonded to the structure of the formula (II) through —OR 1 —, and the Y region is bonded through —OR 2 —.
- Examples of the structure of the formula (II) include the following formulas (II-1) to (II-9).
- n and m are the same as the formula (II).
- q is an integer of 0 to 10.
- n, m and q are not particularly limited and are as described above.
- alkyl includes, for example, a linear or branched alkyl group.
- the number of carbon atoms of the alkyl is not particularly limited, and is, for example, 1 to 30, preferably 1 to 6, and more preferably 1 to 4.
- alkyl group examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, n-heptyl, Examples thereof include n-octyl, n-nonyl, n-decyl and the like.
- Preferred examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl and the like.
- alkenyl includes, for example, linear or branched alkenyl.
- alkenyl include those having one or more double bonds in the alkyl.
- the number of carbon atoms of the alkenyl is not particularly limited, and is the same as, for example, the alkyl, preferably 2 to 8.
- alkenyl include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 3-methyl-2-butenyl and the like.
- alkynyl includes, for example, linear or branched alkynyl.
- alkynyl include those having one or more triple bonds in the alkyl.
- the number of carbon atoms of the alkynyl is not particularly limited, and is the same as, for example, the alkyl, preferably 2 to 8.
- examples of the alkynyl include ethynyl, propynyl, butynyl and the like.
- the alkynyl may further have one or more double bonds, for example.
- aryl includes, for example, a monocyclic aromatic hydrocarbon group and a polycyclic aromatic hydrocarbon group.
- the monocyclic aromatic hydrocarbon group include phenyl and the like.
- the polycyclic aromatic hydrocarbon group include 1-naphthyl, 2-naphthyl, 1-anthryl, 2-anthryl, 9-anthryl, 1-phenanthryl, 2-phenanthryl, 3-phenanthryl, 4-phenanthryl, 9- And phenanthryl.
- Preferable examples include naphthyl such as phenyl, 1-naphthyl and 2-naphthyl.
- heteroaryl includes, for example, a monocyclic aromatic heterocyclic group and a condensed aromatic heterocyclic group.
- heteroaryl include furyl (eg, 2-furyl, 3-furyl), thienyl (eg, 2-thienyl, 3-thienyl), pyrrolyl (eg, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), Imidazolyl (eg, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl), pyrazolyl (eg, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), triazolyl (eg, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-4-yl), tetrazolyl (eg 1-tetrazolyl, 2-tetrazolyl, 5-tetrazolyl), oxazolyl (eg 2-
- cycloalkyl is, for example, a cyclic saturated hydrocarbon group, and the number of carbons is, for example, 3-15.
- the cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, a bridged cyclic hydrocarbon group, a spiro hydrocarbon group, and the like, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. And a bridged cyclic hydrocarbon group.
- the “bridged cyclic hydrocarbon group” includes, for example, bicyclo [2.1.0] pentyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl and bicyclo [3. 2.1] octyl, tricyclo [2.2.1.0] heptyl, bicyclo [3.3.1] nonane, 1-adamantyl, 2-adamantyl and the like.
- examples of the “spiro hydrocarbon group” include spiro [3.4] octyl and the like.
- cycloalkenyl includes, for example, a cyclic unsaturated aliphatic hydrocarbon group, and has, for example, 3 to 7 carbon atoms.
- examples of the cycloalkenyl include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and the like, and preferably cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and the like.
- the cycloalkenyl includes, for example, a bridged cyclic hydrocarbon group and a spiro hydrocarbon group having an unsaturated bond in the ring.
- arylalkyl includes, for example, benzyl, 2-phenethyl, naphthalenylmethyl and the like
- cycloalkylalkyl or “cyclylalkyl” includes, for example, cyclohexylmethyl, adamantylmethyl and the like.
- hydroxyalkyl include hydroxymethyl and 2-hydroxyethyl.
- alkoxy includes, for example, the alkyl-O— group, and examples thereof include methoxy, ethoxy, n-propoxy, isopropoxy, and n-butoxy.
- Alkoxyalkyl includes, for example, Examples thereof include methoxymethyl and the like, and “aminoalkyl” includes, for example, 2-aminoethyl and the like.
- heterocyclyl is, for example, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, pyrrolidinone, 1-imidazolinyl, 2-imidazolinyl, 4-imidazolinyl, 1 -Imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, imidazolidinone, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, piperidinone, piperidinyl, 2-piperidinyl 4-piperidinyl, 1-piperazinyl, 2-piperazinyl, piperazinone, 2-morpholinyl, 3-morpholinyl, morpholino, tetrahydropyranyl, tetra
- heterocyclylalkyl includes, for example, piperidinylmethyl, piperazinylmethyl and the like
- heterocyclylalkenyl includes, for example, 2-piperidinylethenyl and the like
- heteroarylalkyl Examples include pyridylmethyl and quinolin-3-ylmethyl.
- sil includes a group represented by the chemical formula R 3 Si—, and R can be independently selected from the above alkyl, aryl and cycloalkyl, for example, trimethylsilyl group, tert-butyldimethylsilyl
- R can be independently selected from the above alkyl, aryl and cycloalkyl, for example, trimethylsilyl group, tert-butyldimethylsilyl
- the “silyloxy” includes, for example, a trimethylsilyloxy group, and the “silyloxyalkyl” includes, for example, trimethylsilyloxymethyl.
- alkylene includes, for example, methylene, ethylene, propylene and the like.
- the various groups described above may be substituted.
- substituents include hydroxy, carboxy, sulfo, halogen, alkyl halide (haloalkyl, eg, CF 3 , CH 2 CF 3 , CH 2 CCl 3 ), nitro, nitroso, cyano, alkyl (eg, methyl, ethyl).
- alkenyl eg, vinyl
- alkynyl eg, ethynyl
- cycloalkyl eg, cyclopropyl, adamantyl
- cycloalkylalkyl eg, cyclohexylmethyl, adamantylmethyl
- cycloalkenyl eg, : Cyclopropenyl
- cyclylalkyl hydroxyalkyl (eg, hydroxymethyl, hydroxyethyl), alkoxyalkyl (eg, methoxymethyl, ethoxymethyl, ethoxyethyl), aryl (eg, phenyl, naphthyl), arylalkyl
- alkenyl eg, vinyl
- alkynyl eg, ethynyl
- cycloalkyl eg, cyclopropyl, adamantyl
- cycloalkylalkyl e
- the artificial match-type miRNA of the present invention may contain, for example, a labeling substance and may be labeled with the labeling substance.
- the labeling substance is not particularly limited, and examples thereof include fluorescent substances, dyes, isotopes and the like.
- the labeling substance include fluorophores such as pyrene, TAMRA, fluorescein, Cy3 dye, and Cy5 dye, and examples of the dye include Alexa dye such as Alexa488.
- the isotope include a stable isotope and a radioactive isotope, and preferably a stable isotope.
- the stable isotope does not change the physical properties of the labeled compound, for example, and is excellent in properties as a tracer.
- the stable isotope is not particularly limited, and examples thereof include 2 H, 13 C, 15 N, 17 O, 18 O, 33 S, 34 S, and 36 S.
- the artificial match-type miRNA of the present invention can suppress the expression of the target gene. Therefore, the artificial match-type miRNA of the present invention can be used as a therapeutic agent for diseases caused by genes, for example.
- the disease can be treated, for example, by suppressing the expression of the target gene.
- “treatment” includes, for example, the meanings of preventing the disease, improving the disease, and improving the prognosis.
- the disease is not particularly limited, and for example, the expression suppression sequence can be appropriately set according to the target disease.
- Examples of the disease include breast cancer, lung cancer, stomach cancer, colon cancer, liver cancer, pancreatic cancer, esophageal cancer, prostate cancer, gallbladder cancer, uterine body cancer, cervical cancer, and ovarian cancer.
- diseases such as osteosarcoma, cancer such as leukemia, pulmonary fibrosis, liver fibrosis and the like.
- the method for using the artificial match-type miRNA of the present invention is not particularly limited, and for example, the artificial match-type miRNA may be administered to an administration subject having the target gene.
- Examples of the administration subject include cells, tissues, and organs.
- Examples of the administration subject include non-human animals such as humans and non-human mammals other than humans.
- the administration may be, for example, in vivo or in vitro .
- the cells are not particularly limited, and examples thereof include various cultured cells such as HeLa cells, 293 cells, NIH3T3 cells, and COS cells, stem cells such as ES cells and hematopoietic stem cells, and cells isolated from living bodies such as primary cultured cells. can give.
- the target gene to be subject to expression suppression is not particularly limited, and a desired gene can be set. And as above-mentioned, what is necessary is just to select the said mature miRNA according to the kind of said target gene.
- composition of the present invention expression suppression method, treatment method and the like described later can be referred to.
- the artificial match-type miRNA of the present invention can suppress the expression of a target gene as described above, it is useful, for example, as a research tool for pharmaceuticals, diagnostic agents, agricultural chemicals, agriculture, medicine, life sciences and the like. is there.
- the method for synthesizing the artificial match-type miRNA of the present invention is not particularly limited, and conventionally known nucleic acid production methods can be employed.
- the synthesis method include a synthesis method using a genetic engineering technique, a chemical synthesis method, and the like.
- genetic engineering techniques include in vitro transcription synthesis, a method using a vector, and a method using a PCR cassette.
- the vector is not particularly limited, and examples thereof include non-viral vectors such as plasmids and viral vectors.
- the chemical synthesis method is not particularly limited, and examples thereof include a phosphoramidite method and an H-phosphonate method. In the chemical synthesis method, for example, a commercially available automatic nucleic acid synthesizer can be used.
- amidite is generally used.
- the amidite is not particularly limited, and examples of commercially available amidites include RNA Phosphoramidates (2′-O-TBDMSi, trade name, Michisato Pharmaceutical), ACE amidite, TOM amidite, CEE amidite, CEM amidite, TEM amidite, and the like. Can be given.
- the composition for suppressing expression of the present invention is a composition for suppressing the expression of a target gene, and includes the artificial match-type miRNA of the present invention. .
- the composition of the present invention is characterized by including the artificial match-type miRNA of the present invention, and other configurations are not limited at all.
- the expression suppressing composition of the present invention can also be referred to as an expression suppressing reagent, for example.
- expression of the target gene can be suppressed by administration to a subject in which the target gene exists.
- the pharmaceutical composition of the present invention is characterized by containing the artificial match-type miRNA of the present invention.
- the composition of the present invention is characterized by containing the artificial match-type miRNA of the present invention, and other configurations are not limited at all.
- the pharmaceutical composition of the present invention can also be referred to as a pharmaceutical product, for example.
- treatment includes, for example, the meanings of prevention of the above-mentioned diseases, improvement of the diseases, and improvement of the prognosis.
- the disease to be treated is not particularly limited, and examples thereof include diseases caused by gene expression.
- a gene causing the disease is set as the target gene, and further, a guide strand sequence of the mature miRNA may be selected according to the target gene.
- composition for suppressing expression and the pharmaceutical composition (hereinafter referred to as composition) of the present invention
- the method for using the composition for suppressing expression and the pharmaceutical composition (hereinafter referred to as composition) of the present invention is not particularly limited.
- the artificial match-type miRNA is administered to an administration subject having the target gene. do it.
- Examples of the administration subject include cells, tissues, and organs.
- Examples of the administration subject include non-human animals such as humans and non-human mammals other than humans.
- the administration may be, for example, in vivo or in vitro .
- the cells are not particularly limited, and examples thereof include various cultured cells such as HeLa cells, 293 cells, NIH3T3 cells, and COS cells, stem cells such as ES cells and hematopoietic stem cells, and cells isolated from living bodies such as primary cultured cells. can give.
- the administration method is not particularly limited, and can be appropriately determined according to the administration subject, for example.
- the administration subject is a cultured cell
- examples thereof include a method using a transfection reagent and an electroporation method.
- composition of the present invention may contain, for example, only the artificial match-type miRNA of the present invention, or may further contain other additives.
- the additive is not particularly limited, and for example, a pharmaceutically acceptable additive is preferable.
- the type of the additive is not particularly limited, and can be appropriately selected depending on, for example, the type of administration target.
- the artificial match miRNA may form a complex with the additive, for example.
- the additive can also be referred to as a complexing agent, for example.
- the complex formation for example, the artificial match miRNA can be efficiently delivered.
- the complexing agent is not particularly limited, and examples thereof include a polymer, cyclodextrin, adamantine and the like.
- examples of the cyclodextrin include a linear cyclodextrin copolymer and a linear oxidized cyclodextrin copolymer.
- Examples of the additive include a carrier, a binding substance to a target cell, a condensing agent, a fusing agent, an excipient, and the like.
- the expression suppression method of the present invention is a method of suppressing the expression of a target gene, characterized by using the artificial match-type miRNA of the present invention.
- the expression suppression method of the present invention is characterized by using the artificial match-type miRNA of the present invention, and other steps and conditions are not limited at all.
- the mechanism for suppressing the expression of the target gene is not particularly limited, and examples thereof include expression suppression by mature miRNA.
- the expression suppression method of the present invention includes, for example, a step of administering the artificial match-type miRNA to a subject in which the target gene is present.
- the artificial match type miRNA is brought into contact with the administration subject.
- the administration subject include cells, tissues, and organs.
- the administration subject include non-human animals such as humans and non-human mammals other than humans.
- the administration may be, for example, in vivo or in vitro .
- the artificial match-type miRNA may be administered alone, or the composition of the present invention containing the artificial match-type miRNA may be administered.
- the administration method is not particularly limited, and can be appropriately selected depending on, for example, the type of administration target.
- the treatment method of the disease of the present invention comprises the step of administering the artificial match-type miRNA of the present invention to a patient, wherein the guide strand sequence in the artificial match-type miRNA is the above-mentioned It is a guide strand sequence of a mature miRNA that suppresses the expression of a gene involved in a disease.
- the treatment method of the present invention is characterized by using the artificial match-type miRNA of the present invention, and other steps and conditions are not limited at all.
- the expression suppression method of the present invention can be used.
- the administration method is not particularly limited, and may be, for example, oral administration or parenteral administration.
- the use of the present invention is use of the artificial match-type miRNA of the present invention for suppressing expression of the target gene.
- the single-stranded nucleic acid of the present invention is a single-stranded nucleic acid for use in the treatment of a disease, and the single-stranded nucleic acid is the artificial match-type miRNA of the present invention, and the artificial match-type miRNA described above
- the guide strand sequence is a guide strand sequence of a mature miRNA that suppresses the expression of a gene involved in the disease.
- Example 1 Based on the guide strand of mature miR-34a, the artificial match-type miRNA of the present invention was synthesized, and suppression of proliferation of H1299 cells was confirmed.
- an X region composed of the guide strand (SEQ ID NO: 1) and an additional sequence, and a Y region composed of a sequence completely complementary to the X region and an overhang are represented by the following formulae: Matched miR-34a linked via the non-nucleotide structure of the proline derivative (represented by [P] in the sequence) was synthesized.
- the underlined portion corresponds to the guide strand.
- the non-nucleotide structure in the matched miRNA is represented by the following formula, and was introduced by using L-proline diamide amidite (see WO2012 / 017919) in the synthesis of the matched miRNA.
- a match-type miR-34a scramble comprising a guide strand in which the base composition of the guide strand was scrambled and a corresponding passenger strand was synthesized.
- Mature miR-34a Guide strand (SEQ ID NO: 1) 5'- UGGCAGUGUCUUAGCUGGUUGU -3 ' Passenger strand (SEQ ID NO: 6) 5'-CAAUCAGCAAGUAUACUGCCCU-3 ' Mature miR-34a scrambled guide strand (SEQ ID NO: 7) 5'- UGUAUCGUUAUCGGGUCGGUUG -3 ' Passenger strand (SEQ ID NO: 8) 5'-CAACCGACCCGAUAACGAUACA-3 ' Matched miR-34a (SEQ ID NO: 9) 5'- UGGCAGUGUCUUAGCUGGUUGU UCC- [P] -GGAACAACCAGCUAAGACACUGCCAUA-3 ' Match-type miR-34a scramble (SEQ ID NO: 10) 5'- UGUAUCGUUAUCGG
- the cells were cultured in the above-mentioned medium, and the culture solution was dispensed into a 24-well plate at 500 ⁇ L at 1 ⁇ 10 4 cells / well. Furthermore, after culturing the cells in the well for 24 hours, the miRNA was transfected using a transfection reagent RNAi MAX Transfection Reagent (trade name, Life Technologies) according to the attached protocol.
- the composition per well was set as follows. In the following composition, (B) is Opti-MEM (trade name, Invitrogen), (C) is the RNA solution, and 49 ⁇ L of both was added. In the well, the final concentration of the miRNA was 100 nmol / L. After transfection, the cells in the wells were cultured for 3 days. And after the culture
- FIG. 2 is a graph showing the number of cells per well.
- “Normal” is an untreated cell
- “Mock” is a cell into which only a transfection reagent is introduced
- “Scramble” is a miR-34a scramble of a negative control
- “miR-34a” is a positive control.
- the mature miR-34a, “Scramble match” indicates the negative control match-type miR-34a scramble
- “miR-34a match” indicates the result of the match-type miR-34a of the example (hereinafter the same).
- the match-type miR-34a of the example was able to reduce the cell number to the same extent as the mature miR-34a of the positive control.
- FIG. 3 is a graph showing relative values of cell proliferation.
- the match type miR-34a of the example was able to reduce the number of cells to the same extent as the positive miR-34a of the positive control.
- FIG. 4 is a graph showing early apoptosis (%) and late apoptosis (%).
- the match-type miR-34a of the example was able to enhance apoptosis to the same extent as the mature miR-34a of the positive control.
- reverse transcriptase (trade name: M-MLV reverse transcriptase, Invitrogen) was used to synthesize cDNA from the RNA according to the attached protocol. Then, quantitative PCR was performed using the synthesized cDNA as a template, and the amounts of AXL cDNA and MET cDNA were measured. GAPDH cDNA was used as an internal control, and the amount of the cDNA was measured together.
- FIG. 5 (A) shows the result of AXL mRNA
- FIG. 5 (B) shows the result of MET mRNA.
- the match-type miR-34a of the example showed a decrease in the amount of AXL mRNA and the amount of MET mRNA, similar to the mature miR-34a of the positive control. For this reason, it can be said that the transcription
- mold miRNA is also suppressed.
- the match type miR-34a of the example suppresses the expression of AXL mRNA, MET mRNA, and the like, and can suppress the proliferation of H1299 cells and enhance apoptosis.
- the artificial match-type miRNA is a single-stranded nucleic acid molecule, so that it is not necessary to anneal each single strand during use, and TLR3 involved in innate immunity. It is also possible to avoid being recognized.
- Example 2 For the match type miR-34a of Example 1, the additional sequence in the X region and the overhang in the Y region were shortened.
- match-type miR-34a has a 3 base-long additional sequence (J) surrounded by a square on the 3 ′ side of the X region, and on the 5 ′ side of the Y region. It has an overhang (O) with a length of 2 bases surrounded by a square. Therefore, a molecule in which the additional sequence is deleted by one base from the 3 ′ side and the corresponding Y region side sequence is deleted by one base from the 5 ′ side, and the overhang is deleted by one base from the 3 ′ side.
- a lost molecule and a molecule in which the additional sequence and the overhang were deleted one by one were synthesized, and in the same manner as in Example 1, suppression of expression of AXL mRNA and MET mRNA was confirmed.
- the 5 ′ side region of [P] is the X region, and in the X region, the underlined portion is the guide strand sequence, and the other is the additional sequence, and the 3 ′ side region of [P] Is a Y region, and in the Y region, a region surrounded by a square is an overhang.
- FIG. 6 shows the results of AXL mRNA
- FIG. 7 shows the results of MET mRNA.
- Example 3 For the matched miR-34a, the non-nucleotide structure of the linker was altered and the additional sequence in the X region was increased or decreased, and the effect of suppressing the expression of AXL mRNA and MET RNA was examined.
- match-type miR-34a (PH-0039) in which the base sequence of the overhang portion was modified was synthesized from match-type miR-34a of Example 1. Further, a molecule in which the additional sequence of PH-0039 and the corresponding Y region side sequence are deleted (PH-0037), and a molecule in which the additional sequence and the corresponding Y region side sequence are extended to 5 bases (PH -0093) was synthesized.
- the non-nucleotide structure was introduced by using terephthalate amidite (see WO2013 / 133221).
- GlyGly in the chemical formula (G2) is an atomic group represented by the following chemical formula (GlyGly), provided that the terminal carbonyl carbon in the chemical formula (GlyGly) is bonded to the N atom in the chemical formula (G2).
- the terminal nitrogen atom in the following chemical formula (GlyGly) is bonded to the carbonyl carbon of the chemical formula (G2).
- molecules (KH-0007 and KH-0011) were synthesized by substituting the linker regions of PH-0037 and PH-0039 with the non-nucleotide structure of the lysine derivative represented by the following formula (represented by [K] in the sequence), respectively.
- the non-nucleotide structure of the glycine derivative is glycinamide amidite (see WO2013 / 103146)
- the non-nucleotide structure of the glycylglycine derivative is glycylglycinamide amidite (see WO2013 / 133221)
- the non-nucleotide structure of a lysine derivative Were introduced by using L-lysine amide amidites (see WO2013 / 103146), respectively.
- each linker is an X region, and in the X region, the underlined portion is the guide strand sequence, the other is the additional sequence, and the 3 ′ region of each linker is Y It is an area.
- PH-0000 SEQ ID NO: 31
- a molecule NM-0004 in which the mature miR-34a guide strand and passenger strand are joined by the loop portion of the natural pre-miRNA and the mature miRNA guide strand and its completely complementary sequence were annealed.
- a double-stranded matched RNA (NI-0209) was synthesized.
- NM-0004 (SEQ ID NO: 32) 5'- UGGCAGUGUCUUAGCUGGUUGU UGUGAGCAAUAGUAAGGAAGCAAUCAGCAAGUAUACUGCCCU-3 ' NI-0209 Guide strand (SEQ ID NO: 1) / passenger strand (SEQ ID NO: 33) 5'-UGGCAGUGUCUUAGCUGGUUGU-3 '/ 5'-AACCAGCUAAGACACUGCCACU-3'
- RNA was dissolved in distilled water for injection (Otsuka Pharmaceutical Co., Ltd.) so as to be 4 ⁇ mol / L to prepare an RNA solution.
- H1299 cells As cells, H1299 cells (ATCC) were used.
- the medium used was RPMI Medium 1640 (Life Technologies) containing 10% FBS.
- the culture conditions were 37 ° C. and 5% CO 2 .
- the cells were cultured in the above-mentioned medium, and the culture solution was dispensed into a 24-well plate in a volume of 400 ⁇ L at 4 ⁇ 10 4 cells / well.
- the RNA was transfected using the transfection reagent Lipofectamine RNAiMAX (Life Technologies) according to the protocol attached to the transfection reagent.
- the composition per well was set as follows, and transfection was performed.
- (B) is Opti-MEM (Life Technologies)
- C) is 0.4 ⁇ mol / L and 2 ⁇ mol / L of the RNA solution, and 98.5 ⁇ L of both were added.
- the final concentration of RNA was 2 nmol / L.
- PCR was performed using the synthesized cDNA as a template, and the expression levels of the AXL and MET genes and the expression level of the GAPDH gene as an internal standard were measured. The expression levels of the AXL and MET genes were corrected by the expression level of the GAPDH gene.
- LightCycler 480 SYBR Green I Master (trade name, Roche) was used as a reagent
- LightCycler 480 Instrument II (trade name, Roche) was used as a device (hereinafter the same).
- the following primer sets were used for amplification of the AXL, MET, and GAPDH genes, respectively.
- PCR primer set for AXL gene (SEQ ID NO: 11) 5'-CTCAACCAGGACGACTCCAT-3 ' (SEQ ID NO: 12) 5'-AGACCGCTTCACTCAGGAAA-3 ' PCR primer set for MET gene (SEQ ID NO: 13) 5'-CAGGCAGTGCAGCATGTAGT-3 ' (SEQ ID NO: 14) 5'-TGTCCAACAAAGTCCCATGA-3 ' GAPDH gene primer set (SEQ ID NO: 15) 5'-ATGGGGAAGGTGAAGGTCG-3 ' (SEQ ID NO: 16) 5'-GGGTCATTGATGGCAACAATATC-3 '
- the gene expression level was also measured for cells in which only 100 ⁇ L of the solution (B) was added to the culture solution ( ⁇ ).
- the RNA solution was not added, and the cells treated in the same manner except that (A) 1.5 ⁇ L and (B) were added in total 100 ⁇ L were also used for gene expression. The amount was measured (mock).
- the expression level in control cells was taken as 1, and the relative value of the expression level in cells into which each RNA was introduced was determined.
- Example 4 Based on the guide strand of mature let-7a, various artificial match-type miRNAs of the present invention were synthesized, and the effect of suppressing the expression of the target gene, HMGA2 mRNA, was examined.
- an X region consisting of a guide chain sequence of mature let-7a and an additional sequence (0, 3 or 5 bases in length) thereof, a completely complementary to the X region, and 5 ′ side
- a proline derivative ([P]) a proline derivative ([P])
- TP] terephthalic acid derivative
- Gly glycine derivative
- glycylglycine a proline derivative between the Y region having an overhang of 2 bases in length
- Various artificial match-type let-7a into which a linker of a derivative ([GlyGly]) and a lysine derivative ([K]) was introduced was synthesized.
- each linker is an X region, and in the X region, the underlined portion is the guide strand sequence, the other is the additional sequence, and the 3 ′ region of each linker is Y It is an area.
- RNA was dissolved in distilled water for injection (Otsuka Pharmaceutical Co., Ltd.) so as to be 0.4 ⁇ mol / L to prepare an RNA solution.
- A549 cells (DS Pharma Biomedical) were used.
- DMEM fetal bovine serum
- FBS fetal bovine serum
- the cells were cultured in the above-mentioned medium, and the culture solution was dispensed into a 24-well plate in a volume of 400 ⁇ L at 4 ⁇ 10 4 cells / well.
- the RNA was transfected using the transfection reagent Lipofectamine RNAiMAX (Life Technologies) according to the protocol attached to the transfection reagent.
- the composition per well was set as follows, and transfection was performed.
- (B) is Opti-MEM (Life Technologies)
- C) is 0.1 ⁇ mol / L and 0.2 ⁇ mol / L of the RNA solution, and 98.5 ⁇ L of both were added together.
- the final concentration of RNA was 0.2 nmol / L.
- PCR was performed using the synthesized cDNA as a template, and the expression level of the HMGA2 gene and the expression level of the GAPDH gene as an internal standard were measured.
- LightCycler 480 SYBR Green I Master (trade name, Roche) was used as a reagent
- LightCycler 480 Instrument II (trade name, Roche) was used as a device (hereinafter the same).
- the following primer sets were used for amplification of the HMGA2 gene and GAPDH gene, respectively.
- PCR primer set for HMGA2 gene (SEQ ID NO: 39) 5'-GAAGCCACTGGAGAAAAACG-3 ' (SEQ ID NO: 40) 5′-CTTCGGCAGACTCTTGTGAG-3 ′ GAPDH gene primer set (SEQ ID NO: 15) 5'-ATGGGGAAGGTGAAGGTCG-3 ' (SEQ ID NO: 16) 5'-GGGTCATTGATGGCAACAATATC-3 '
- the gene expression level was also measured for cells in which only 100 ⁇ L of the solution (B) was added to the culture solution ( ⁇ ).
- the RNA solution was not added, and the cells treated in the same manner except that (A) 1.5 ⁇ L and (B) were added in total 100 ⁇ L were also used for gene expression. The amount was measured (mock).
- the expression level in the cells of the control was taken as 1, and the relative value of the expression level in the cells into which each RNA was introduced was determined.
- the match-type let-7a of the example shows the expression of HMGA2 mRNA at the same level or higher than that of the positive control mature let-7a or double-stranded match-type let-7a. Suppressed. Moreover, even if the non-nucleotide structure of the linker region and the base length of the additional sequence of the X region were modified, the effect of suppressing the expression of HMGA2 mRNA was maintained.
- Example 5 Based on the guide strand of mature miR-29b, various artificial match-type miRNAs of the present invention were synthesized, and the effect of suppressing the expression of the target gene COLA1 mRNA was examined.
- NM-0005 (SEQ ID NO: 42) 5'-GCUGGUUUCAUAUGGUGGUUUAGAUUUAAAUAGUGAUUGUC UAGCACCAUUUGAAAUCAGUGUU -3 ' NI-0211 Passenger strand (SEQ ID NO: 41) / guide strand (SEQ ID NO: 5) 5'-CACUGAUUUCAAAUGGUGCUAGA-3 '/ 5'- UAGCACCAUUUGAAAUCAGUGUU -3'
- an X region consisting of a guide strand sequence of mature miR-29b and an additional sequence (0, 3 or 5 bases length) on the 3 ′ side thereof, a complete complement to the X region, and the 5 ′ side
- a proline derivative ([P]) a proline derivative ([P])
- TP] terephthalic acid derivative
- Gly glycine derivative
- glycylglycine a glycylglycine between the Y region having an overhang of 2 bases in length
- Various artificial match type miR-29b into which a linker of a derivative ([GlyGly]) and a lysine derivative ([K]) was introduced was synthesized.
- each linker is an X region, and in the X region, the underlined portion is the guide strand sequence, the other is the additional sequence, and the 3 ′ region of each linker is Y It is an area.
- RNA was dissolved in distilled water for injection (Otsuka Pharmaceutical Co., Ltd.) so as to be 1 ⁇ mol / L to prepare an RNA solution.
- A549 cells (DS Pharma Biomedical) were used.
- DMEM fetal bovine serum
- FBS fetal bovine serum
- the cells were cultured in the above-mentioned medium, and the culture solution was dispensed into a 24-well plate in a volume of 400 ⁇ L at 4 ⁇ 10 4 cells / well.
- the RNA was transfected using the transfection reagent Lipofectamine RNAiMAX (Life Technologies) according to the protocol attached to the transfection reagent.
- the composition per well was set as follows, and transfection was performed.
- (B) is Opti-MEM (Life Technologies)
- C) is 0.4 ⁇ mol / L and 2 ⁇ mol / L of the RNA solution, and 98.5 ⁇ L of both were added.
- the final concentration of RNA was 0.5 nmol / L.
- PCR was performed using the synthesized cDNA as a template, and the expression level of the COL1A1 gene and the expression level of the GAPDH gene as an internal standard were measured.
- LightCycler 480 SYBR Green I Master (trade name, Roche) was used as a reagent
- LightCycler 480 Instrument II (trade name, Roche) was used as a device (hereinafter the same).
- the following primer sets were used for the amplification of the COL1A1 gene and the GAPDH gene, respectively.
- PCR primer set for COL1A1 gene (SEQ ID NO: 46) 5'-CCCAAGGACAAGAGGCATGT-3 ' (SEQ ID NO: 47) 5′-CCGCCATACTCGAACTGGAA-3 ′ GAPDH gene primer set (SEQ ID NO: 15) 5'-ATGGGGAAGGTGAAGGTCG-3 ' (SEQ ID NO: 16) 5'-GGGTCATTGATGGCAACAATATC-3 '
- the gene expression level was also measured for cells in which only 100 ⁇ L of the solution (B) was added to the culture solution ( ⁇ ).
- the RNA solution was not added, and the cells treated in the same manner except that (A) 1.5 ⁇ L and (B) were added in total 100 ⁇ L were also used for gene expression. The amount was measured (mock).
- the expression level in the cells of the control was set to 1, and the relative value of the expression level in the cells into which each RNA was introduced was determined.
- the match-type miR-29b of the example shows the expression of COLA1 mRNA at the same level or higher than that of the positive control mature miR-29b and the double-stranded match-type miR-29b. Suppressed. Moreover, even when the non-nucleotide structure of the linker region and the base length of the additional sequence of the X region were modified, the COLA1 mRNA expression inhibitory effect was maintained.
- the artificial match-type miRNA of the present invention can be easily synthesized at low cost, and can suppress the translation of the protein encoded by the gene. Since the artificial match-type miRNA of the present invention can suppress the expression of a target gene as described above, it is useful, for example, as a research tool for pharmaceuticals, diagnostic agents, agricultural chemicals, agriculture, medicine, life sciences, and the like. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
X領域とY領域とを有する一本鎖核酸であり、
前記X領域の3’末端と前記Y領域の5’末端とが、非ヌクレオチド構造のリンカー領域を介して連結し、
前記X領域は、成熟miRNAのガイド鎖配列を含み、
前記Y領域は、前記X領域と完全に相補な配列を含むことを特徴とする。
本発明の人工マッチ型miRNAは、前述のように、
X領域とY領域とを有する一本鎖核酸であり、
前記X領域の3’末端と前記Y領域の5’末端とが、非ヌクレオチド構造のリンカー領域を介して連結し、
前記X領域は、成熟miRNAのガイド鎖配列を含み、
前記Y領域は、前記X領域と完全に相補な配列を含むことを特徴とする。
オーバーハングの長さ(O)=[Y領域の全長の塩基数(Y)]-[X領域の全長の塩基数(X)]
hsa-miR-34a(配列番号1)
UGGCAGUGUCUUAGCUGGUUGU
hsa-let-7a(配列番号2)
UGAGGUAGUAGGUUGUAUAGUU
hsa-let-7f(配列番号3)
UGAGGUAGUAGAUUGUAUAGUU
hsa-miR-150(配列番号4)
UCUCCCAACCCUUGUACCAGUG
hsa-miR-29b(配列番号5)
UAGCACCAUUUGAAAUCAGUGUU
ここで、各配列番号で示されるヌクレオチド配列は、ガイド鎖配列を示す。
let-7aのガイド鎖は、例えば、HMGA2(high mobility group AT-hook 2)、KRAS、NRAS、HRAS、MYC、TLR4等をターゲットとし、これらの標的遺伝子の発現抑制により、例えば、肺がん、大腸がん、胃がん、肝がん、乳がん等の疾患を予防または治療できる。
let-7fのガイド鎖は、例えば、HMGA2(high mobility group AT-hook 2)、KRAS、NRAS、HRAS、MYC、TLR4等をターゲットとし、これらの標的遺伝子の発現抑制により、例えば、肺がん、大腸がん、胃がん、肝がん、乳がん等の疾患を予防または治療できる。
miR-150のガイド鎖は、例えば、COL1A1、COL4A4、SMAD2、SP1等をターゲットとし、これらの標的遺伝子の発現抑制により、例えば、肺線維症、肝線維症等の疾患を予防または治療できる。
miR-29bのガイド鎖は、例えば、COL1A1、MCL1、DNMT3A、DNMT3B、TCL1A、TGFb3等をターゲットとし、これらの標的遺伝子の発現抑制により、例えば、肺がん、大腸がん、胃がん、肝がん、乳がん、肺線維症、肝線維症等の疾患を予防または治療できる。
Q11およびQ12は、それぞれ独立して、単結合、CH2(メチレン基)、NH(イミノ基)、C=O(カルボニル基)、C=S(チオカルボニル基)、C=NH(イミノメチレン基)、O、またはSであり、
Q1およびQ2は、それぞれ独立して、単結合、CH2(メチレン基)、NH(イミノ基)、C=O(カルボニル基)、C=S(チオカルボニル基)、C=NH(イミノメチレン基)、O、またはSであり、
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
L1は、n個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換されても置換されていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
mは、0~30の範囲の整数であり;
nは、0~30の範囲の整数であり;
前記X領域および前記Y領域は、それぞれ、-OR1-または-OR2-を介して、前記リンカー残基に結合し、
ここで、R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(I-0)であり、
Aは、任意の原子団である。
条件(1)
前記X領域は、-OR2-を介して、前記Y領域は、-OR1-を介して、前記式(I)の構造と結合する。
条件(2)
前記X領域は、-OR1-を介して、前記Y領域は、-OR2-を介して、前記式(I)の構造と結合する。
R100は、任意の置換基であり、存在しても存在しなくてもよく、存在する場合は、1個でも複数でもよく、複数の場合は、互いに同一でも異なっていてもよい。R100における前記任意の置換基としては、例えば、前記Ra、Rb、RcおよびRdにおいて例示する後述の置換基が挙げられ、より具体的には、例えば、ハロゲン、ヒドロキシ、アルコキシ、アミノ、カルボキシ、スルホ、ニトロ、カルバモイル、スルファモイル、アルキル、アルケニル、アルキニル、ハロアルキル、アリール、アリールアルキル、アルキルアリール、シクロアルキル、シクロアルケニル、シクロアルキルアルキル、シクリルアルキル、ヒドロキシアルキル、アルコキシアルキル、アミノアルキル、シリル、シリルオキシアルキル、ピロールイル、イミダゾリル、等があげられる。また、前記化学式(Iα2)の構造が、下記化学式(Iα3)で表されることがさらに好ましい。
R100は、任意の置換基であり、存在しても存在しなくてもよく、存在する場合は、1個でも複数でもよく、複数の場合は、互いに同一でも異なっていてもよい。具体的には、例えば、前記化学式(Iα2)中のR100と同様である。また、前記化学式(Iβ2)の構造が、下記化学式(Iβ3)で表されることがさらに好ましい。
前記microRNAの配列に対する相補的配列は、それぞれ、-OR1-または-OR2-を介して、前記アミノ酸残基に結合し、
ここで、R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(I)であり、
Aは、任意の原子団であり、ただし、下記化学式(Ia)は、アミノ酸またはペプチドである。
R100は、任意の置換基であり、存在しても存在しなくてもよく、存在する場合は、1個でも複数でもよく、複数の場合は、互いに同一でも異なっていてもよい。R100における前記任意の置換基としては、例えば、前記Ra、Rb、RcおよびRdで例示した置換基が挙げられ、より具体的には、例えば、ハロゲン、ヒドロキシ、アルコキシ、アミノ、カルボキシ、スルホ、ニトロ、カルバモイル、スルファモイル、アルキル、アルケニル、アルキニル、ハロアルキル、アリール、アリールアルキル、アルキルアリール、シクロアルキル、シクロアルケニル、シクロアルキルアルキル、シクリルアルキル、ヒドロキシアルキル、アルコキシアルキル、アミノアルキル、シリル、シリルオキシアルキル、ピロールイル、イミダゾリル、等があげられる。また、前記化学式(Ia2)の構造は、例えば、下記化学式(Ia3)であってもよい。
X1およびX2は、それぞれ独立して、H2、O、SまたはNHであり;
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
R3は、環A上のC-3、C-4、C-5またはC-6に結合する水素原子または置換基であり、
L1は、n個の原子からなるアルキレン鎖であり、ここで、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の原子からなるアルキレン鎖であり、ここで、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換されても置換れていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
lは、1または2であり;
mは、0~30の範囲の整数であり;
nは、0~30の範囲の整数であり;
環Aは、前記環A上のC-2以外の1個の炭素原子が、窒素、酸素、硫黄で置換されてもよく、
前記環A内に、炭素-炭素二重結合または炭素-窒素二重結合を含んでもよく、
前記X領域および前記Y領域は、それぞれ、-OR1-または-OR2-を介して、前記非ヌクレオチド構造に結合し、
ここで、R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(II)である。
条件(1)
前記X領域は、-OR2-を介して、前記Y領域は、-OR1-を介して、前記式(II)の構造と結合する。
条件(2)
前記X領域は、-OR1-を介して、前記Y領域は、-OR2-を介して、前記式(II)の構造と結合する。
本発明の発現抑制用組成物は、前述のように、標的遺伝子の発現を抑制するための組成物であって、前記本発明の人工マッチ型miRNAを含むことを特徴とする。本発明の組成物は、前記本発明の人工マッチ型miRNAを含むことが特徴であり、その他の構成は、何ら制限されない。本発明の発現抑制用組成物は、例えば、発現抑制用試薬ということもできる。
本発明の発現抑制方法は、前述のように、標的遺伝子の発現を抑制する方法であって、前記本発明の人工マッチ型miRNAを使用することを特徴とする。本発明の発現抑制方法は、前記本発明の人工マッチ型miRNAを使用することが特徴であって、その他の工程および条件は、何ら制限されない。
本発明の疾患の治療方法は、前述のように、前記本発明の人工マッチ型miRNAを、患者に投与する工程を含み、前記人工マッチ型miRNAにおける前記ガイド鎖配列が、前記疾患に関与する遺伝子の発現を抑制する成熟miRNAのガイド鎖配列であることを特徴とする。本発明の治療方法は、前記本発明の人工マッチ型miRNAを使用することが特徴であって、その他の工程および条件は、何ら制限されない。
本発明の使用は、前記標的遺伝子の発現抑制のための、前記本発明の人工マッチ型miRNAの使用である。
成熟miR-34aのガイド鎖に基づいて、本発明の人工マッチ型miRNAを合成し、H1299細胞の増殖の抑制を確認した。
ポジティブコントロールのmiRNAとして、以下に示すガイド鎖(配列番号1)およびパッセンジャー鎖(配列番号6)からなるヒト成熟miR-34aを合成した。また、ネガティブコントロールとして、前記ガイド鎖の塩基組成をスクランブルにしたガイド鎖スクランブル(配列番号7)とそれに対するパッセンジャー鎖(配列番号8)とからなる成熟miR-34aスクランブルを合成した。
成熟miR-34a
ガイド鎖(配列番号1)
5’-UGGCAGUGUCUUAGCUGGUUGU-3’
パッセンジャー鎖(配列番号6)
5’-CAAUCAGCAAGUAUACUGCCCU-3’
成熟miR-34aスクランブル
ガイド鎖(配列番号7)
5’-UGUAUCGUUAUCGGGUCGGUUG-3’
パッセンジャー鎖(配列番号8)
5’-CAACCGACCCGAUAACGAUACA-3’
マッチ型miR-34a(配列番号9)
5’-UGGCAGUGUCUUAGCUGGUUGUUCC-[P]-GGAACAACCAGCUAAGACACUGCCAUA-3’
マッチ型miR-34aスクランブル(配列番号10)
5’-UGUAUCGUUAUCGGGUCGGUUGUCC-[P]-GGACAACCGACCCGAUAACGAUACAUA-3’
前記人工マッチ型miRNAを、ヒト非小細胞性肺がん細胞株(NCI-H1299)に導入し、前記細胞への影響を確認した。
前記miRNAを、注射用蒸留水(大塚製薬、以下同様)で溶解し、100μmol/LのmiRNA溶液を調製した。培地は、10%FBSを含むRPMI-1640(Invitrogen)を使用し、培養条件は、37℃、5%CO2下とした。
培養後の培養細胞について、ウェルあたりの細胞数をカウントした。この結果を、図2に示す。図2は、ウェルあたりの細胞数を示すグラフである。図2において、「Normal」は、未処理の細胞、「Mock」は、トランスフェクション試薬のみを導入した細胞、「Scramble」は、ネガティブコントロールのmiR-34aスクランブル、「miR-34a」は、ポジティブコントロールの成熟miR-34a、「Scramble match」は、ネガティブコントロールのマッチ型miR-34aスクランブル、「miR-34a match」は、実施例のマッチ型miR-34aの結果を示す(以下、同様)。図2に示すように、実施例のマッチ型miR-34aは、ポジティブコントロールの成熟miR-34aと同程度に、細胞数を減少できた。
培養後の培養細胞について、市販の試薬キット(商品名 Cell Count Reagent SF、ナカライテスク社)を用いてMTTアッセイを行い、細胞増殖を評価した。細胞増殖の評価は、Normal(無処置)の結果を1として、相対値により表した。この結果を、図3に示す。図3は、細胞増殖の相対値を示すグラフである。図3に示すように、実施例のマッチ型miR-34aは、ポジティブコントロールの成熟miR-34aと同程度に、細胞数を減少できた。
培養後の培養細胞について、市販の試薬キット(商品名Annexin V:PE Apoptosis Detection Kit、BD Biosciences社)を用いてアポトーシスの検出を行った。この結果を、図4に示す。図4は、早期アポトーシス(%)と後期アポトーシス(%)とを示すグラフである。図4に示すように、実施例のマッチ型miR-34aは、ポジティブコントロールの成熟miR-34aと同程度に、アポトーシスを亢進できた。
培養後の培養細胞について、ISOGEN reagent(商品名、ニッポンジーン)を用い、添付のプロトコールに従って、RNAを回収した。
5’-CTCAACCAGGACGACTCCAT-3’ (配列番号11)
5’-AGACCGCTTCACTCAGGAAA-3’ (配列番号12)
MET プライマーセット
5’-CAGGCAGTGCAGCATGTAGT-3’ (配列番号13)
5’-TGTCCAACAAAGTCCCATGA-3’ (配列番号14)
GAPDH プライマーセット
5’-ATGGGGAAGGTGAAGGTCG-3’ (配列番号15)
5’-GGGTCATTGATGGCAACAATATC-3’ (配列番号16)
実施例1のマッチ型miR-34aについて、X領域の付加配列およびY領域のオーバーハングの短縮化を行った。
以下に示すように、マッチ型miR-34aは、X領域の3’側に四角で囲んだ3塩基長の付加配列(J)を有し、Y領域の5’側に四角で囲んだ2塩基長のオーバーハング(O)を有している。そこで、前記付加配列を3’側から1塩基ずつ欠失させ且つそれに対応するY領域側の配列を5’側から1塩基ずつ欠失させた分子、オーバーハングを3’側から1塩基ずつ欠失させた分子、および、前記付加配列とオーバーハングとを1塩基ずつ欠失させた分子を合成し、前記実施例1と同様にして、AXL mRNAおよびMET mRNAの発現抑制を確認した。下記配列において、[P]の5’側領域がX領域であり、前記X領域において、下線部は前記ガイド鎖配列であり、その他が、前記付加配列であり、[P]の3’側領域がY領域であり、前記Y領域において、四角で囲んだ領域がオーバーハングである。
マッチ型miR-34aについて、リンカーの非ヌクレオチド構造の改変およびX領域の付加配列の増減を行い、AXL mRNAおよびMET RNAの発現抑制効果を調べた。
以下に示すように、実施例1のマッチ型miR-34aから、オーバーハング部分の塩基配列を改変したマッチ型miR-34a(PH-0039)を合成した。さらに、PH-0039の付加配列およびそれに対応するY領域側の配列を欠失させた分子(PH-0037)、付加配列およびそれに対応するY領域側の配列を5塩基長に延長した分子(PH-0093)を合成した。
また、PH-0037、PH-0039およびPH-0093のリンカー領域を、下記式のテレフタル酸誘導体の非ヌクレオチド構造(配列において[TP]で表す)にそれぞれ置換した分子(XH-0016、XH-0025およびXH-0027)を合成した。該非ヌクレオチド構造は、テレフタル酸アミダイト(WO2013/133221参照)を使用することにより導入した。
PH-0037(配列番号28)
5’-UGGCAGUGUCUUAGCUGGUUGU-[P]-ACAACCAGCUAAGACACUGCCACU-3’
PH-0039(配列番号29)
5’-UGGCAGUGUCUUAGCUGGUUGUUCC-[P]-GGAACAACCAGCUAAGACACUGCCACU-3’
PH-0093(配列番号30)
5’-UGGCAGUGUCUUAGCUGGUUGUUCCGG-[P]-CCGGAACAACCAGCUAAGACACUGCCACU-3’
XH-0016(配列番号28)
5’-UGGCAGUGUCUUAGCUGGUUGU-[TP]-ACAACCAGCUAAGACACUGCCACU-3’
XH-0025(配列番号29)
5’-UGGCAGUGUCUUAGCUGGUUGUUCC-[TP]-GGAACAACCAGCUAAGACACUGCCACU-3’
XH-0027(配列番号30)
5’-UGGCAGUGUCUUAGCUGGUUGUUCCGG-[TP]-CCGGAACAACCAGCUAAGACACUGCCACU-3’
XH-0012(配列番号28)
5’-UGGCAGUGUCUUAGCUGGUUGU-[Gly]-ACAACCAGCUAAGACACUGCCACU-3’
XH-0028(配列番号29)
5’-UGGCAGUGUCUUAGCUGGUUGUUCC-[Gly]-GGAACAACCAGCUAAGACACUGCCACU-3’
XH-0014(配列番号28)
5’-UGGCAGUGUCUUAGCUGGUUGU-[GlyGly]-ACAACCAGCUAAGACACUGCCACU-3’
XH-0029(配列番号29)
5’-UGGCAGUGUCUUAGCUGGUUGUUCC-[GlyGly]-GGAACAACCAGCUAAGACACUGCCACU-3’
KH-0007(配列番号28)
5’-UGGCAGUGUCUUAGCUGGUUGU-[K]-ACAACCAGCUAAGACACUGCCACU-3’
KH-0011(配列番号29)
5’-UGGCAGUGUCUUAGCUGGUUGUUCC-[K]-GGAACAACCAGCUAAGACACUGCCACU-3’
また、ネガティブコントロールとして、核酸データベース上で登録されているすべての配列に相補性を有さない配列からなるガイド鎖とそれに対応するパッセンジャー鎖とからなるマッチ型miRNA(PH-0000)を合成した。
PH-0000(配列番号31)
5’-UACUAUUCGACACGCGAAGUUCC-[P]-GGAACUUCGCGUGUCGAAUAGUAUU-3’
ポジティブコントロールとして、成熟miR-34aのガイド鎖とパッセンジャー鎖を天然型pre-miRNAのループ部分でつないだ分子(NM-0004)および成熟miRNAのガイド鎖とそれに完全相補的な配列とをアニーリングさせた二本鎖マッチ型RNA(NI-0209)を合成した。
5’-UGGCAGUGUCUUAGCUGGUUGUUGUGAGCAAUAGUAAGGAAGCAAUCAGCAAGUAUACUGCCCU-3’
NI-0209
ガイド鎖(配列番号1)/パッセンジャー鎖(配列番号33)
5’-UGGCAGUGUCUUAGCUGGUUGU-3’/5’-AACCAGCUAAGACACUGCCACU-3’
前記各RNAを、4μmol/Lとなるように、注射用蒸留水(大塚製薬)に溶解し、RNA溶液を調製した。
AXL遺伝子用PCRプライマーセット
(配列番号11) 5’-CTCAACCAGGACGACTCCAT-3’
(配列番号12) 5’-AGACCGCTTCACTCAGGAAA-3’
MET遺伝子用PCRプライマーセット
(配列番号13) 5’-CAGGCAGTGCAGCATGTAGT-3’
(配列番号14) 5’-TGTCCAACAAAGTCCCATGA-3’
GAPDH遺伝子用プライマーセット
(配列番号15) 5’-ATGGGGAAGGTGAAGGTCG-3’
(配列番号16) 5’-GGGTCATTGATGGCAACAATATC-3’
図6および7に示すように、リンカー領域の非ヌクレオチド構造を改変しても、また、X領域の付加配列を欠失もしくは延長しても、AXL mRNAおよびMET RNAの発現抑制効果は維持された。
成熟let-7aのガイド鎖に基づいて、種々の本発明の人工マッチ型miRNAを合成し、標的遺伝子であるHMGA2 mRNAの発現抑制効果を調べた。
ポジティブコントロールとして、成熟let-7aのガイド鎖(配列番号2)とパッセンジャー鎖(配列番号34)を天然型pre-let-7aのループ部分でつないだ分子(NM-0003)および成熟let-7aのガイド鎖とそれに完全相補的な配列とをアニーリングさせた二本鎖マッチ型RNA(NI-0207)を合成した。
NM-0003(配列番号35)
5’-UGAGGUAGUAGGUUGUAUAGUUUUAGGGUCACACCCACCACUGGGAGAUAACUAUACAAUCUACUGUCUUUC-3’
NI-0207
ガイド鎖(配列番号2)/パッセンジャー鎖(配列番号34)
5’-UGAGGUAGUAGGUUGUAUAGUU-3’/5’-CUAUACAACCUACUACCUCAUC-3’
PH-0013(配列番号36)
5’-UGAGGUAGUAGGUUGUAUAGUU-[P]-AACUAUACAACCUACUACCUCAUC-3’
PH-0015(配列番号37)
5’-UGAGGUAGUAGGUUGUAUAGUUUCC-[P]-GGAAACUAUACAACCUACUACCUCAUC-3’
PH-0094(配列番号38)
5’-UGAGGUAGUAGGUUGUAUAGUUUCCGG-[P]-CCGGAAACUAUACAACCUACUACCUCAUC-3’
XH-0010(配列番号36)
5’-UGAGGUAGUAGGUUGUAUAGUU-[TP]-AACUAUACAACCUACUACCUCAUC-3’
XH-0030(配列番号37)
5’-UGAGGUAGUAGGUUGUAUAGUUUCC-[TP]-GGAAACUAUACAACCUACUACCUCAUC-3’
XH-0031(配列番号38)
5’-UGAGGUAGUAGGUUGUAUAGUUUCCGG-[TP]-CCGGAAACUAUACAACCUACUACCUCAUC-3’
XH-0008(配列番号36)
5’-UGAGGUAGUAGGUUGUAUAGUU-[Gly]-AACUAUACAACCUACUACCUCAUC-3’
XH-0032(配列番号37)
5’-UGAGGUAGUAGGUUGUAUAGUUUCC-[Gly]-GGAAACUAUACAACCUACUACCUCAUC-3’
XH-0009(配列番号36)
5’-UGAGGUAGUAGGUUGUAUAGUU-[GlyGly]-AACUAUACAACCUACUACCUCAUC-3’
XH-0033(配列番号37)
5’-UGAGGUAGUAGGUUGUAUAGUUUCC-[GlyGly]-GGAAACUAUACAACCUACUACCUCAUC-3’
KH-0005(配列番号36)
5’-UGAGGUAGUAGGUUGUAUAGUU-[K]-AACUAUACAACCUACUACCUCAUC-3’
KH-0012(配列番号37)
5’-UGAGGUAGUAGGUUGUAUAGUUUCC-[K]-GGAAACUAUACAACCUACUACCUCAUC-3’
また、ネガティブコントロールとして、実施例3で合成したPH-0000を使用した。
前記各RNAを、0.4μmol/Lとなるように、注射用蒸留水(大塚製薬)に溶解し、RNA溶液を調製した。
HMGA2遺伝子用PCRプライマーセット
(配列番号39) 5’-GAAGCCACTGGAGAAAAACG-3’
(配列番号40) 5’-CTTCGGCAGACTCTTGTGAG-3’
GAPDH遺伝子用プライマーセット
(配列番号15) 5’-ATGGGGAAGGTGAAGGTCG-3’
(配列番号16) 5’-GGGTCATTGATGGCAACAATATC-3’
図10に示すように、実施例のマッチ型let-7aは、ポジティブコントロールの成熟let-7aや二本鎖マッチ型let-7aと同程度もしくはそれ以上に、HMGA2 mRNAの発現を抑制した。また、リンカー領域の非ヌクレオチド構造や、X領域の付加配列の塩基長を改変しても、HMGA2 mRNAの発現抑制効果は維持された。
成熟miR-29bのガイド鎖に基づいて、種々の本発明の人工マッチ型miRNAを合成し、標的遺伝子であるCOLA1 mRNAの発現抑制効果を調べた。
ポジティブコントロールとして、成熟miR-29bのガイド鎖(配列番号5)とパッセンジャー鎖(配列番号41)を天然型pre-miR-29bのループ部分でつないだ分子(NM-0005)および成熟miR-29bのガイド鎖とそれに完全相補的な配列とをアニーリングさせた二本鎖マッチ型RNA(NI-0211)を合成した。
NM-0005(配列番号42)
5’-GCUGGUUUCAUAUGGUGGUUUAGAUUUAAAUAGUGAUUGUCUAGCACCAUUUGAAAUCAGUGUU-3’
NI-0211
パッセンジャー鎖(配列番号41)/ガイド鎖(配列番号5)
5’-CACUGAUUUCAAAUGGUGCUAGA-3’/5’-UAGCACCAUUUGAAAUCAGUGUU-3’
PH-0071(配列番号43)
5’-UAGCACCAUUUGAAAUCAGUGUU-[P]-AACACUGAUUUCAAAUGGUGCUAGA-3’
PH-0073(配列番号44)
5’-UAGCACCAUUUGAAAUCAGUGUUUCC-[P]-GGAAACACUGAUUUCAAAUGGUGCUAGA-3’
PH-0095(配列番号45)
5’-UAGCACCAUUUGAAAUCAGUGUUUCCGG-[P]-CCGGAAACACUGAUUUCAAAUGGUGCUAGA-3’
XH-0034(配列番号43)
5’-UAGCACCAUUUGAAAUCAGUGUU-[TP]-AACACUGAUUUCAAAUGGUGCUAGA-3’
XH-0035(配列番号44)
5’-UAGCACCAUUUGAAAUCAGUGUUUCC-[TP]-GGAAACACUGAUUUCAAAUGGUGCUAGA-3’
XH-0036(配列番号45)
5’-UAGCACCAUUUGAAAUCAGUGUUUCCGG-[TP]-CCGGAAACACUGAUUUCAAAUGGUGCUAGA-3’
XH-0037(配列番号43)
5’-UAGCACCAUUUGAAAUCAGUGUU-[Gly]-AACACUGAUUUCAAAUGGUGCUAGA-3’
XH-0038(配列番号44)
5’-UAGCACCAUUUGAAAUCAGUGUUUCC-[Gly]-GGAAACACUGAUUUCAAAUGGUGCUAGA-3’
XH-0039(配列番号43)
5’-UAGCACCAUUUGAAAUCAGUGUU-[GlyGly]-AACACUGAUUUCAAAUGGUGCUAGA-3’
XH-0040(配列番号44)
5’-UAGCACCAUUUGAAAUCAGUGUUUCC-[GlyGly]-GGAAACACUGAUUUCAAAUGGUGCUAGA-3’
KH-0013(配列番号43)
5’-UAGCACCAUUUGAAAUCAGUGUU-[K]-AACACUGAUUUCAAAUGGUGCUAGA-3’
KH-0014(配列番号44)
5’-UAGCACCAUUUGAAAUCAGUGUUUCC-[K]-GGAAACACUGAUUUCAAAUGGUGCUAGA-3’
また、ネガティブコントロールとして、実施例3で合成したPH-0000を使用した。
前記各RNAを、1μmol/Lとなるように、注射用蒸留水(大塚製薬)に溶解し、RNA溶液を調製した。
COL1A1遺伝子用PCRプライマーセット
(配列番号46) 5’-CCCAAGGACAAGAGGCATGT-3’
(配列番号47) 5’-CCGCCATACTCGAACTGGAA-3’
GAPDH遺伝子用プライマーセット
(配列番号15) 5’-ATGGGGAAGGTGAAGGTCG-3’
(配列番号16) 5’-GGGTCATTGATGGCAACAATATC-3’
図11に示すように、実施例のマッチ型miR-29bは、ポジティブコントロールの成熟miR-29bや二本鎖マッチ型miR-29bと同程度もしくはそれ以上に、COLA1 mRNAの発現を抑制した。また、リンカー領域の非ヌクレオチド構造や、X領域の付加配列の塩基長を改変しても、COLA1 mRNAの発現抑制効果は維持された。
Claims (51)
- X領域とY領域とを有する一本鎖核酸であり、
前記X領域の3’末端と前記Y領域の5’末端とが、非ヌクレオチド構造のリンカー領域を介して連結し、
前記X領域は、成熟miRNAのガイド鎖配列を含み、
前記Y領域は、前記X領域と完全に相補な配列を含むことを特徴とする、人工マッチ型miRNA。 - 前記Y領域と前記X領域とをアライメントした際に、前記Y領域が、3’末端にオーバーハングを有する、請求項1記載の人工マッチ型miRNA。
- 前記オーバーハングが、0~4塩基長である、請求項2記載の人工マッチ型miRNA。
- 前記X領域が、前記ガイド鎖配列と付加配列とからなり、前記付加配列が、前記ガイド鎖配列の3’末端に連結している、請求項1から3のいずれか一項に記載の人工マッチ型miRNA。
- 前記X領域における前記付加配列の長さが、0~5塩基長である、請求項4記載の人工マッチ型miRNA。
- 前記X領域の長さが、19~33塩基長である、請求項1から5のいずれか一項に記載の人工マッチ型miRNA。
- 前記Y領域の長さが、21~35塩基長である、請求項1から6のいずれか一項に記載の人工マッチ型miRNA。
- 全長が、40~68塩基長である、請求項1から7のいずれか一項に記載の人工マッチ型miRNA。
- 前記リンカー領域が、アミノ酸残基、ポリアミン残基、およびポリカルボン酸残基からなる群から選択される少なくとも一つを含む請求項1から8のいずれか一項に記載の人工マッチ型miRNA。
- 前記リンカー領域が、ポリカルボン酸残基を含む、請求項9に記載の人工マッチ型miRNA。
- 前記ポリカルボン酸残基が、テレフタル酸残基である、請求項10に記載の人工マッチ型miRNA。
- 前記リンカー領域が、アミノ酸残基を含む、請求項9に記載の人工マッチ型miRNA。
- 前記アミノ酸残基が、グリシン残基、テレフタル酸アミド残基、プロリン残基またはリシン残基である、請求項12に記載の人工マッチ型miRNA。
- 前記アミノ酸残基が、複数のアミノ酸残基が連結したものである、請求項12または13に記載の人工マッチ型miRNA。
- 前記複数のアミノ酸残基が連結したものが、グリシン二量体または三量体の残基である、請求項14に記載の人工マッチ型miRNA。
- 前記リンカー残基が、下記化学式(I-0)で表される請求項1から15のいずれか一項に記載の人工マッチ型miRNA。
Q11およびQ12は、それぞれ独立して、単結合、CH2(メチレン基)、NH(イミノ基)、C=O(カルボニル基)、C=S(チオカルボニル基)、C=NH(イミノメチレン基)、O、またはSであり、
Q1およびQ2は、それぞれ独立して、単結合、CH2(メチレン基)、NH(イミノ基)、C=O(カルボニル基)、C=S(チオカルボニル基)、C=NH(イミノメチレン基)、O、またはSであり、
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
L1は、n個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換されても置換されていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
mは、0~30の範囲の整数であり;
nは、0~30の範囲の整数であり;
前記X領域および前記Y領域は、それぞれ、-OR1-または-OR2-を介して、前記リンカー残基に結合し、
ここで、R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(I-0)であり、
Aは、任意の原子団である。 - 前記化学式(I-0)中、Q11およびQ12が、それぞれカルボニル基である請求項16記載の人工マッチ型miRNA。
- 前記化学式(I-0)中、Q1およびQ2が、それぞれイミノ基である請求項17記載の人工マッチ型miRNA。
- 前記化学式(I-0)中、Q11およびQ12が、それぞれイミノ基である請求項16記載の人工マッチ型miRNA。
- 前記化学式(I-0)中、Q1およびQ2が、それぞれカルボニル基である請求項21記載の人工マッチ型miRNA。
- 前記リンカー領域が、アミノ酸残基を含み、前記アミノ酸残基が、下記化学式(I)で表される請求項1から3および6から10のいずれか一項に記載の人工マッチ型miRNA。
X1およびX2は、それぞれ独立して、H2、O、SまたはNHであり;
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
L1は、n個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の炭素原子を有するアルキレン鎖であり、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換されても置換されていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
mは、0~30の範囲の整数であり;
nは、0~30の範囲の整数であり;
前記X領域および前記Y領域は、それぞれ、-OR1-または-OR2-を介して、前記アミノ酸残基に結合し、
ここで、R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(I)であり、
Aは、任意の原子団であり、ただし、下記化学式(Ia)は、アミノ酸またはペプチドである。
- 前記アミノ酸残基における前記アミノ酸が、天然アミノ酸および人工アミノ酸の少なくとも一方である請求項1から3、6から10および20のいずれか一項に記載の人工マッチ型miRNA。
- 前記天然アミノ酸が、タンパク質を構成するアミノ酸である請求項26記載の人工マッチ型miRNA。
- 前記アミノ酸残基における前記アミノ酸が、グリシン、α-アラニン、アルギニン、アスパラギン、アスパラギン酸、システイン、シスチン、グルタミン、グルタミン酸、ヒスチジン、イソロイシン、ロイシン、リシン、ヒドロキシリシン、メチオニン、フェニルアラニン、セリン、トレオニン、チロシン、バリン、プロリン、4-ヒドロキシプロリン、トリプトファン、β-アラニン、1-アミノ-2-カルボキシシクロペンタン、アミノ安息香酸、アミノピリジンカルボン酸および下記化学式(Ia2)で表されるアミノ酸からなる群から選択される少なくとも1種類であり、前記アミノ酸は、さらに置換基または保護基を有していても有していなくても良い、請求項1から9、12から15、25および26のいずれか一項に記載の人工マッチ型miRNA。
R100は、任意の置換基であり、存在しても存在しなくてもよく、存在する場合は、1個でも複数でもよく、複数の場合は、互いに同一でも異なっていてもよい。 - 前記化学式(I-1)において、n=11およびm=12、またはn=5およびm=4である、請求項30記載の人工マッチ型miRNA。
- 前記化学式(I-4)において、n=5およびm=4である、請求項30記載の人工マッチ型miRNA。
- 前記化学式(I-6)において、n=4およびm=4である、請求項30記載の人工マッチ型miRNA。
- 前記化学式(I-7)において、n=5およびm=4である、請求項30記載の人工マッチ型miRNA。
- 前記リンカー領域の非ヌクレオチド構造が、ピロリジン骨格およびピペリジン骨格の少なくとも一方を含む、請求項1から9、12および13のいずれか一項に記載の人工マッチ型miRNA。
- 前記非ヌクレオチド構造が、下記式(II)で表わされる、請求項1から8のいずれか一項に記載の人工マッチ型miRNA。
X1およびX2は、それぞれ独立して、H2、O、SまたはNHであり;
Y1およびY2は、それぞれ独立して、単結合、CH2、NH、OまたはSであり;
R3は、環A上のC-3、C-4、C-5またはC-6に結合する水素原子または置換基であり;
L1は、n個の原子からなるアルキレン鎖であり、ここで、アルキレン炭素原子上の水素原子は、OH、ORa、NH2、NHRa、NRaRb、SH、もしくはSRaで置換されても置換されていなくてもよく、または、
L1は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y1が、NH、OまたはSの場合、Y1に結合するL1の原子は炭素であり、OR1に結合するL1の原子は炭素であり、酸素原子同士は隣接せず;
L2は、m個の原子からなるアルキレン鎖であり、ここで、アルキレン炭素原子上の水素原子は、OH、ORc、NH2、NHRc、NRcRd、SHもしくはSRcで置換され
ても置換されていなくてもよく、または、
L2は、前記アルキレン鎖の一つ以上の炭素原子が、酸素原子で置換されたポリエーテル鎖であり、
ただし、Y2が、NH、OまたはSの場合、Y2に結合するL2の原子は炭素であり、OR2に結合するL2の原子は炭素であり、酸素原子同士は隣接せず;
Ra、Rb、RcおよびRdは、それぞれ独立して、置換基または保護基であり;
lは、1または2であり;
mは、0~30の範囲の整数であり;
nは、0~30の範囲の整数であり;
環Aは、前記環A上のC-2以外の1個の炭素原子が、窒素、酸素または硫黄で置換されてもよく、
前記環A内に、炭素-炭素二重結合または炭素-窒素二重結合を含んでもよく、
前記X領域および前記Y領域は、それぞれ、-OR1-または-OR2-を介して、前記非ヌクレオチド構造に結合し、
ここで、R1およびR2は、存在しても存在しなくてもよく、存在する場合、R1およびR2は、それぞれ独立して、ヌクレオチド残基または前記構造(I)である。 - 前記X領域は、hsa-miR-34、hsa-miR-29およびhsa-let-7からなる群から選択される成熟miRNAのガイド鎖配列を含む、請求項1から36のいずれか一項に記載の人工マッチ型miRNA。
- 前記成熟miRNAが、hsa-miR-34aである、請求項37記載の人工マッチ型miRNA。
- ヌクレオチド配列が、配列番号9および17~28からなる群から選択されるヌクレオチド配列である、請求項38記載の人工マッチ型miRNA。
- 前記成熟miRNAが、hsa-let-7aである、請求項37記載の人工マッチ型miRNA。
- ヌクレオチド配列が、配列番号36~38からなる群から選択されるヌクレオチド配列である、請求項40記載の人工マッチ型miRNA。
- 前記成熟miRNAが、hsa-miR-29bである、請求項37記載の人工マッチ型miRNA。
- ヌクレオチド配列が、配列番号43~45からなる群から選択されるヌクレオチド配列である、請求項42記載の人工マッチ型miRNA。
- 標的遺伝子の発現を抑制するための組成物であって、
請求項1から43のいずれか一項に記載の人工マッチ型miRNAを含むことを特徴とする、発現抑制用組成物。 - 請求項1から43のいずれか一項に記載の人工マッチ型miRNAを含むことを特徴とする、薬学的組成物。
- 標的遺伝子の発現を抑制する方法であって、
請求項1から43のいずれか一項に記載の人工マッチ型miRNAを使用することを特徴とする、発現抑制方法。 - 前記人工マッチ型miRNAを、細胞、組織または器官に投与する工程を含む、請求項46記載の発現抑制方法。
- 前記人工マッチ型miRNAを、in vivoまたはin vitroで投与する、請求項46または47記載の発現抑制方法。
- 前記人工マッチ型miRNAを、非ヒト動物に投与する、請求項46または47記載の発現抑制方法。
- 疾患の治療方法であって、
請求項1から43のいずれか一項に記載の人工マッチ型miRNAを、患者に投与する工程を含み、
前記人工マッチ型miRNAにおける前記ガイド鎖配列が、前記疾患に関与する遺伝子の発現を抑制する成熟miRNAのガイド鎖配列であることを特徴とする、治療方法。 - 疾患の治療に使用するための一本鎖核酸であって、
前記一本鎖核酸は、請求項1から43のいずれか一項に記載の人工マッチ型miRNAであり、
前記人工マッチ型miRNAにおける前記ガイド鎖配列が、前記疾患に関与する遺伝子の発現を抑制する成熟miRNAのガイド鎖配列であることを特徴とする、一本鎖核酸。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2935022A CA2935022A1 (en) | 2013-12-27 | 2014-12-27 | Artificial match-type mirna for controlling gene expression and use therefor |
AU2014370829A AU2014370829B2 (en) | 2013-12-27 | 2014-12-27 | Artificial match-type miRNA for controlling gene expression and use therefor |
SG11201605247XA SG11201605247XA (en) | 2013-12-27 | 2014-12-27 | Artificial match-type mirna for controlling gene expression and use therefor |
MX2016008518A MX2016008518A (es) | 2013-12-27 | 2014-12-27 | Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo. |
BR112016014986-6A BR112016014986A2 (ja) | 2013-12-27 | 2014-12-27 | Artificial match type miRNA and its use for gene expression control |
KR1020167020185A KR102357337B1 (ko) | 2013-12-27 | 2014-12-27 | 유전자 발현 제어를 위한 인공 매치형 miRNA 및 그 용도 |
EP14874254.7A EP3088525A4 (en) | 2013-12-27 | 2014-12-27 | Artificial match-type mirna for controlling gene expression and use therefor |
CN201480076467.2A CN106068324B (zh) | 2013-12-27 | 2014-12-27 | 控制基因表达的人工匹配型miRNA及其用途 |
US15/108,453 US10934542B2 (en) | 2013-12-27 | 2014-12-27 | Artificial match-type miRNA for controlling gene expression and use therefor |
JP2015555078A JP6425142B2 (ja) | 2013-12-27 | 2014-12-27 | 遺伝子発現制御のための人工マッチ型miRNAおよびその用途 |
RU2016130611A RU2697094C2 (ru) | 2013-12-27 | 2014-12-27 | ИСКУССТВЕННАЯ мкРНК С СООТВЕТСТВИЕМ ДЛЯ КОНТРОЛЯ ЭКСПРЕССИИ ГЕНОВ И ЕЕ ПРИМЕНЕНИЕ |
IL246395A IL246395B (en) | 2013-12-27 | 2016-06-22 | Artificial coordination type micro rna for controlling gene expression and its use |
IL271715A IL271715B (en) | 2013-12-27 | 2019-12-25 | Artificial coordination type micro rna for controlling gene expression and its use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-273033 | 2013-12-27 | ||
JP2013273033 | 2013-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015099187A1 true WO2015099187A1 (ja) | 2015-07-02 |
Family
ID=53479025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/084724 WO2015099187A1 (ja) | 2013-12-27 | 2014-12-27 | 遺伝子発現制御のための人工マッチ型miRNAおよびその用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10934542B2 (ja) |
EP (1) | EP3088525A4 (ja) |
JP (2) | JP6425142B2 (ja) |
KR (1) | KR102357337B1 (ja) |
CN (2) | CN112646812A (ja) |
AU (1) | AU2014370829B2 (ja) |
BR (1) | BR112016014986A2 (ja) |
CA (1) | CA2935022A1 (ja) |
IL (2) | IL246395B (ja) |
MX (1) | MX2016008518A (ja) |
RU (1) | RU2697094C2 (ja) |
SG (3) | SG10201913570XA (ja) |
WO (1) | WO2015099187A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016167366A1 (ja) * | 2015-04-17 | 2016-10-20 | 国立大学法人 東京大学 | 眼疾患治療剤 |
WO2017131237A1 (ja) * | 2016-01-30 | 2017-08-03 | 株式会社ボナック | 人工単一ガイドrna及びその用途 |
CN108350457A (zh) * | 2015-10-30 | 2018-07-31 | 株式会社博纳克 | 稳定地含有抑制TGF-β1基因的表达的单链核酸分子的组合物 |
WO2018143475A1 (ja) | 2017-02-06 | 2018-08-09 | 日産化学工業株式会社 | 一本鎖オリゴヌクレオチド |
WO2018155487A1 (ja) * | 2017-02-21 | 2018-08-30 | 株式会社ボナック | 核酸含有dpi用粉末製剤及びその用途 |
US20180326091A1 (en) * | 2014-12-27 | 2018-11-15 | Bonac Corporation | NATURALLY OCCURRING miRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME |
WO2019156020A1 (ja) * | 2018-02-09 | 2019-08-15 | 住友化学株式会社 | 核酸分子の製造方法 |
WO2019182037A1 (ja) | 2018-03-20 | 2019-09-26 | 国立大学法人東京工業大学 | 毒性が低減されたアンチセンスオリゴヌクレオチド |
US11142769B2 (en) | 2015-03-27 | 2021-10-12 | Bonac Corporation | Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109810977A (zh) | 2012-05-26 | 2019-05-28 | 株式会社博纳克 | 具有递送功能的基因表达调控用单链核酸分子 |
CN105899663B (zh) | 2013-12-26 | 2019-07-26 | 学校法人东京医科大学 | 用于基因表达控制的人工模拟miRNA及其用途 |
JP6425142B2 (ja) | 2013-12-27 | 2018-11-21 | 株式会社ボナック | 遺伝子発現制御のための人工マッチ型miRNAおよびその用途 |
CN116064544A (zh) | 2016-01-26 | 2023-05-05 | 日产化学株式会社 | 单链寡核苷酸 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008519606A (ja) * | 2004-11-12 | 2008-06-12 | アンビオン インコーポレーティッド | miRNAおよびmiRNA阻害分子に関する方法および組成物 |
WO2010056737A2 (en) | 2008-11-11 | 2010-05-20 | Mirna Therapeutics, Inc. | Methods and compositions involving mirnas in cancer stem cells |
WO2012017919A1 (ja) | 2010-08-03 | 2012-02-09 | 株式会社ボナック | 含窒素脂環式骨格を有する一本鎖核酸分子 |
WO2012106591A1 (en) * | 2011-02-03 | 2012-08-09 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-34 |
WO2013103146A1 (ja) | 2012-01-07 | 2013-07-11 | 株式会社ボナック | アミノ酸骨格を有する一本鎖核酸分子 |
JP2013153736A (ja) * | 2012-01-07 | 2013-08-15 | Bonac Corp | ペプチド骨格を有する一本鎖核酸分子 |
WO2013133221A1 (ja) | 2012-03-04 | 2013-09-12 | 株式会社ボナック | microRNA阻害剤 |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE873543C (de) | 1942-10-28 | 1953-04-16 | Basf Ag | Verfahren zur Herstellung von hydroxyl- bzw. sulfhydryl-gruppenhaltigen Dicarbaminsaeureestern |
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4550163A (en) | 1979-02-05 | 1985-10-29 | Abbott Laboratories | Ligand analog-irreversible enzyme inhibitor conjugates |
US20030232355A1 (en) | 1992-05-22 | 2003-12-18 | Isis Pharmaceuticals, Inc. | Double-stranded peptide nucleic acids |
US5631148A (en) | 1994-04-22 | 1997-05-20 | Chiron Corporation | Ribozymes with product ejection by strand displacement |
GB9621367D0 (en) | 1996-10-14 | 1996-12-04 | Isis Innovation | Chiral peptide nucleic acids |
US6197557B1 (en) | 1997-03-05 | 2001-03-06 | The Regents Of The University Of Michigan | Compositions and methods for analysis of nucleic acids |
EP1013770A1 (en) | 1998-12-23 | 2000-06-28 | Université Louis Pasteur de Strasbourg | Non-viral transfection vector |
FR2790757B1 (fr) | 1999-03-09 | 2003-08-01 | Bioalliance Pharma | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant. |
US6852334B1 (en) | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US6962906B2 (en) | 2000-03-14 | 2005-11-08 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
ATE496139T1 (de) | 2001-03-09 | 2011-02-15 | Boston Probes Inc | Kombinationsoligomere betreffende verfahren, kits und zusammensetzungen |
AU2004266311B2 (en) | 2001-05-18 | 2009-07-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US20050233455A1 (en) | 2001-10-29 | 2005-10-20 | Damha Masad J | Acyclic linker-containing oligonucleotides and uses thereof |
US20060111312A1 (en) | 2002-02-22 | 2006-05-25 | The John Hopkins University | Antigene locks and therapeutic uses thereof |
CA2479530A1 (en) | 2002-03-20 | 2003-10-02 | Massachusetts Institute Of Technology | Hiv therapeutic |
SI3222724T1 (sl) | 2002-08-05 | 2019-03-29 | Silence Therapeutics Gmbh | Nadaljnje nove oblike molekul interferenčne RNA |
US20040058886A1 (en) | 2002-08-08 | 2004-03-25 | Dharmacon, Inc. | Short interfering RNAs having a hairpin structure containing a non-nucleotide loop |
US6936651B2 (en) | 2002-12-17 | 2005-08-30 | E. I. Du Pont De Nemours And Company | Compatibility improvement in crystalline thermoplastics with mineral fillers |
JP2006522158A (ja) | 2003-04-03 | 2006-09-28 | アルナイラム ファーマシューティカルズ インコーポレイテッド | iRNA複合体 |
CA2528958A1 (en) | 2003-06-12 | 2004-12-23 | Applera Corporation | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same |
WO2005047505A2 (en) | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
ATE532865T1 (de) | 2003-09-30 | 2011-11-15 | Anges Mg Inc | Klammerartiges oligonukleotid und dieses enthaltender arzneistoff |
US20050222009A1 (en) | 2003-10-14 | 2005-10-06 | Itschak Lamensdorf | Dual phase - PNA conjugates for the delivery of PNA through the blood brain barrier |
US20050209141A1 (en) | 2003-10-17 | 2005-09-22 | Silver Randi B | Mast cell-derived renin |
AU2005327517B2 (en) | 2004-06-30 | 2011-05-26 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
AU2005276245C1 (en) | 2004-08-23 | 2015-02-26 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated introacular pressure by siRNAs |
US7655768B2 (en) | 2004-08-26 | 2010-02-02 | Nippon Shinyaku Co., Ltd. | Galactose derivative, drug carrier and medicinal composition |
CA2594672C (en) | 2004-08-31 | 2014-12-30 | Ana I. Jimenez | Methods and compositions to inhibit p2x7 receptor expression |
JP2008522585A (ja) | 2004-10-12 | 2008-07-03 | ザ ロックフェラー ユニバーシティー | マイクロrna |
JP2008526213A (ja) | 2004-12-30 | 2008-07-24 | トッド エム. ハウザー, | 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法 |
CA2638797A1 (en) | 2006-03-01 | 2007-09-07 | Nippon Shinyaku Co., Ltd. | Galactose derivative, drug carrier and medicinal composition |
CA2651042A1 (en) | 2006-05-05 | 2007-12-13 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
ES2392478T3 (es) * | 2006-05-11 | 2012-12-11 | Alnylam Pharmaceuticals Inc. | Composiciones y métodos para inhibir la expresión del gen PCSK9 |
EP2700638A1 (en) | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purine analogs |
EP1890152A1 (en) | 2006-08-14 | 2008-02-20 | Charite Universitätsmedizin-Berlin | Determination of renin/prorenin receptor activity |
JP2008220366A (ja) | 2007-02-16 | 2008-09-25 | National Institute Of Advanced Industrial & Technology | 修飾型pna/rna複合体 |
JP5145557B2 (ja) | 2007-03-01 | 2013-02-20 | 財団法人ヒューマンサイエンス振興財団 | マイクロrnaを有効成分として含有する腫瘍増殖抑制剤、および癌治療用医薬組成物 |
HUE027018T2 (en) | 2007-03-21 | 2016-08-29 | Brookhaven Science Ass Llc | Combination hairpin antisense compositions and methods for modulating expression |
CN101121934B (zh) * | 2007-04-11 | 2011-12-07 | 哈尔滨医科大学 | 多靶点miRNA反义核苷酸的制备方法 |
WO2008137862A2 (en) * | 2007-05-03 | 2008-11-13 | Rosetta Inpharmatics Llc | Methods of using mir34 as a biomarker for tp53 functional status |
JP5296328B2 (ja) | 2007-05-09 | 2013-09-25 | 独立行政法人理化学研究所 | 1本鎖環状rnaおよびその製造方法 |
US20090123501A1 (en) | 2007-05-17 | 2009-05-14 | Baylor College Of Medicine | Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines |
WO2008147837A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds, non-naturally occurring micro-rnas, and methods for optimizing non-naturally occurring micro-rnas |
DK2164967T3 (en) | 2007-05-31 | 2015-10-19 | Univ Iowa Res Found | Reduction of off-target rna interferenstoksicitet |
US20110212075A1 (en) | 2007-06-25 | 2011-09-01 | Siemens Aktiengesellschaft | Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders |
EP2201022A4 (en) | 2007-08-27 | 2012-01-04 | Boston Biomedical Inc | COMPOSITION OF ASYMMETRIC RNA DUPLEX AS MICRO-RNA MIMETICUM OR INHIBOTOR |
WO2009048932A2 (en) | 2007-10-09 | 2009-04-16 | Children's Medical Center Corporation | Methods to regulate mirna processing by targeting lin-28 |
WO2009047362A2 (en) | 2007-10-12 | 2009-04-16 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Method for opening tight junctions |
TW200927177A (en) | 2007-10-24 | 2009-07-01 | Nat Inst Of Advanced Ind Scien | Lipid-modified double-stranded RNA having potent RNA interference effect |
AR069328A1 (es) | 2007-11-15 | 2010-01-13 | Alcon Mfg Ltd | Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad |
JP2011504730A (ja) | 2007-11-29 | 2011-02-17 | 蘇州瑞博生物技術有限公司 | 標的遺伝子の発現を干渉する複合体分子およびその合成方法 |
EP3156077B1 (en) | 2007-12-04 | 2022-03-09 | Arbutus Biopharma Corporation | Targeting lipids |
US20110159586A1 (en) | 2007-12-07 | 2011-06-30 | Halo-Bio Rnai Therapeutics, Inc. | Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides |
US20110055965A1 (en) | 2008-02-15 | 2011-03-03 | Hiroshi Abe | Cycle single-stranded nucleic acid complex and method for producing the same |
EP2264167B1 (en) | 2008-03-31 | 2016-10-12 | National Institute of Advanced Industrial Science and Technology | Double-stranded lipid-modified rna having high rna interference effect |
US20110172295A1 (en) | 2008-04-11 | 2011-07-14 | The University Of North Carolina At Chapel Hill | METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING |
WO2009143619A1 (en) | 2008-05-27 | 2009-12-03 | Chum | Methods of treating or preventing obesity and obesity-related hypertension |
WO2010058824A1 (ja) | 2008-11-19 | 2010-05-27 | 国立大学法人岐阜大学 | 間葉系細胞の分化を調節するための薬剤及びその利用 |
EP2411518A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Rna interference mediated inhibition of the high affinity ige receptor alpha chain (fcerla) gene expression using short interfering nucleic acid (sina) |
WO2010141511A2 (en) | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
WO2011008730A2 (en) * | 2009-07-13 | 2011-01-20 | Somagenics Inc. | Chemical modification of small hairpin rnas for inhibition of gene expression |
CA2768598A1 (en) | 2009-07-22 | 2011-01-27 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
WO2011028550A1 (en) | 2009-08-24 | 2011-03-10 | Merck Sharp & Dohme Corp. | Segmented micro rna mimetics |
US20110052666A1 (en) | 2009-09-03 | 2011-03-03 | Medtronic, Inc. | Compositions, Methods, and Systems for SIRNA Delivery |
US8871509B2 (en) | 2009-11-06 | 2014-10-28 | Chung-Ang University-Academy Corporation Foundation | Nanoparticle-based gene delivery systems |
EP3494963A1 (en) | 2009-12-18 | 2019-06-12 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
US8933046B2 (en) | 2009-12-23 | 2015-01-13 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Influenza targets |
CA2785492C (en) | 2009-12-23 | 2018-07-24 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
EP3560503B1 (en) | 2010-03-24 | 2021-11-17 | Phio Pharmaceuticals Corp. | Rna interference in dermal and fibrotic indications |
CN101845071B (zh) | 2010-03-25 | 2012-02-01 | 北京欧凯纳斯科技有限公司 | 一种2’或3’偶联氨基酸的核苷衍生物、其制备方法及应用 |
JP5555940B2 (ja) | 2010-04-14 | 2014-07-23 | 国立大学法人佐賀大学 | 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法 |
WO2011132672A1 (ja) | 2010-04-19 | 2011-10-27 | 独立行政法人理化学研究所 | 機能性核酸の安定化法 |
CA2795815C (en) | 2010-04-23 | 2018-06-26 | Cold Spring Harbor Laboratory | Novel structurally designed shrnas |
US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
NZ704812A (en) | 2010-07-08 | 2017-01-27 | Bonac Corp | Single-stranded nucleic acid molecule for controlling gene expression |
US8618073B2 (en) * | 2010-07-22 | 2013-12-31 | The University Of North Carolina At Chapel Hill | Use of miR-29 for cell protection |
US8691782B2 (en) * | 2010-08-03 | 2014-04-08 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
US20130253168A1 (en) | 2010-08-31 | 2013-09-26 | Steven L. Colletti | Novel single chemical entities and methods for delivery of oligonucleotides |
BR112013013522A2 (pt) | 2010-12-02 | 2019-09-24 | Daiichi Sankyo Co Ltd | polinucleotídeo ou um sal deste, composição farmacêutica, uso de um polinucleotídeo ou um sal deste, reagente, composição, e, método para produzir um composto |
CN102559666B (zh) * | 2010-12-18 | 2013-12-25 | 中国科学院上海生命科学研究院 | 抑制植物病毒的人工miRNA及其构建和用途 |
CN102784398B (zh) * | 2011-05-16 | 2014-06-18 | 南京大学 | 内皮抑素作为递送系统和化学合成的rna干扰分子组成的组合物及应用 |
JP6011945B2 (ja) | 2011-05-20 | 2016-10-25 | 公一 中城 | マイクロrna又はその発現系を含む組成物 |
EP2527440A1 (en) | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
JP2013055913A (ja) | 2011-09-09 | 2013-03-28 | Bonac Corp | 遺伝子発現制御のための一本鎖rna分子 |
WO2013077446A1 (ja) | 2011-11-26 | 2013-05-30 | 株式会社ボナック | 遺伝子発現制御のための一本鎖核酸分子 |
AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
CN109810977A (zh) | 2012-05-26 | 2019-05-28 | 株式会社博纳克 | 具有递送功能的基因表达调控用单链核酸分子 |
EP2975938A4 (en) | 2013-03-15 | 2017-02-15 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
EP3828276A1 (en) | 2013-05-22 | 2021-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
WO2015093495A1 (ja) | 2013-12-16 | 2015-06-25 | 株式会社ボナック | TGF-β1遺伝子発現制御のための一本鎖核酸分子 |
CN105899663B (zh) | 2013-12-26 | 2019-07-26 | 学校法人东京医科大学 | 用于基因表达控制的人工模拟miRNA及其用途 |
JP6492014B2 (ja) * | 2013-12-27 | 2019-03-27 | 株式会社ボナック | 遺伝子発現制御のための人工マッチ型miRNAおよびその用途 |
JP6425142B2 (ja) | 2013-12-27 | 2018-11-21 | 株式会社ボナック | 遺伝子発現制御のための人工マッチ型miRNAおよびその用途 |
WO2015161255A1 (en) | 2014-04-18 | 2015-10-22 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy |
BR112017013664A2 (ja) | 2014-12-27 | 2018-03-13 | Bonac Corporation | Naturally occurring type miRNA for gene expression control, and its use |
EP3276003B1 (en) | 2015-03-27 | 2022-07-20 | Bonac Corporation | Single-chain nucleic acid molecule having delivery function and gene expression control ability |
AU2016382055C1 (en) | 2015-12-29 | 2020-06-04 | Bonac Corporation | Single-stranded nucleic acid molecule inhibiting expression of prorenin gene or prorenin receptor gene, and use thereof |
-
2014
- 2014-12-27 JP JP2015555078A patent/JP6425142B2/ja not_active Expired - Fee Related
- 2014-12-27 WO PCT/JP2014/084724 patent/WO2015099187A1/ja active Application Filing
- 2014-12-27 EP EP14874254.7A patent/EP3088525A4/en not_active Withdrawn
- 2014-12-27 SG SG10201913570XA patent/SG10201913570XA/en unknown
- 2014-12-27 SG SG10201805087VA patent/SG10201805087VA/en unknown
- 2014-12-27 BR BR112016014986-6A patent/BR112016014986A2/ja not_active Application Discontinuation
- 2014-12-27 SG SG11201605247XA patent/SG11201605247XA/en unknown
- 2014-12-27 MX MX2016008518A patent/MX2016008518A/es unknown
- 2014-12-27 RU RU2016130611A patent/RU2697094C2/ru active
- 2014-12-27 CN CN202011538569.5A patent/CN112646812A/zh not_active Withdrawn
- 2014-12-27 CN CN201480076467.2A patent/CN106068324B/zh not_active Expired - Fee Related
- 2014-12-27 US US15/108,453 patent/US10934542B2/en active Active
- 2014-12-27 CA CA2935022A patent/CA2935022A1/en not_active Abandoned
- 2014-12-27 KR KR1020167020185A patent/KR102357337B1/ko active IP Right Grant
- 2014-12-27 AU AU2014370829A patent/AU2014370829B2/en not_active Ceased
-
2016
- 2016-06-22 IL IL246395A patent/IL246395B/en active IP Right Grant
-
2018
- 2018-06-13 JP JP2018113017A patent/JP6653889B2/ja not_active Expired - Fee Related
-
2019
- 2019-12-25 IL IL271715A patent/IL271715B/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008519606A (ja) * | 2004-11-12 | 2008-06-12 | アンビオン インコーポレーティッド | miRNAおよびmiRNA阻害分子に関する方法および組成物 |
WO2010056737A2 (en) | 2008-11-11 | 2010-05-20 | Mirna Therapeutics, Inc. | Methods and compositions involving mirnas in cancer stem cells |
WO2012017919A1 (ja) | 2010-08-03 | 2012-02-09 | 株式会社ボナック | 含窒素脂環式骨格を有する一本鎖核酸分子 |
WO2012106591A1 (en) * | 2011-02-03 | 2012-08-09 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-34 |
WO2013103146A1 (ja) | 2012-01-07 | 2013-07-11 | 株式会社ボナック | アミノ酸骨格を有する一本鎖核酸分子 |
JP2013153736A (ja) * | 2012-01-07 | 2013-08-15 | Bonac Corp | ペプチド骨格を有する一本鎖核酸分子 |
WO2013133221A1 (ja) | 2012-03-04 | 2013-09-12 | 株式会社ボナック | microRNA阻害剤 |
Non-Patent Citations (4)
Title |
---|
DEITERS, THE AAPS JOURNAL, vol. 12, 2009, pages 51 - 60 |
J. F. W. MCOMIE: "Protecting Groups in Organic Chemistry", 1973, PRENUM PRESS |
See also references of EP3088525A4 |
TAKESHITA ET AL., MOL. THER., vol. 18, 2010, pages 181 - 187 |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11027023B2 (en) * | 2014-12-27 | 2021-06-08 | Bonac Corporation | Natural type miRNA for controlling gene expression, and use of same |
US20180326091A1 (en) * | 2014-12-27 | 2018-11-15 | Bonac Corporation | NATURALLY OCCURRING miRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME |
US11142769B2 (en) | 2015-03-27 | 2021-10-12 | Bonac Corporation | Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability |
WO2016167366A1 (ja) * | 2015-04-17 | 2016-10-20 | 国立大学法人 東京大学 | 眼疾患治療剤 |
CN108350457A (zh) * | 2015-10-30 | 2018-07-31 | 株式会社博纳克 | 稳定地含有抑制TGF-β1基因的表达的单链核酸分子的组合物 |
JPWO2017131237A1 (ja) * | 2016-01-30 | 2018-11-01 | 株式会社ボナック | 人工単一ガイドrna及びその用途 |
WO2017131237A1 (ja) * | 2016-01-30 | 2017-08-03 | 株式会社ボナック | 人工単一ガイドrna及びその用途 |
CN109072224A (zh) * | 2016-01-30 | 2018-12-21 | 株式会社博纳克 | 人工单导rna及其用途 |
US11518994B2 (en) | 2016-01-30 | 2022-12-06 | Bonac Corporation | Artificial single guide RNA and use thereof |
CN109072224B (zh) * | 2016-01-30 | 2022-07-15 | 株式会社博纳克 | 人工单导rna及其用途 |
EP3409776A4 (en) * | 2016-01-30 | 2019-12-25 | Bonac Corporation | ARN UNIQUE ARTIFICIAL GUIDE AND ITS USE |
JP7096604B2 (ja) | 2016-01-30 | 2022-07-06 | 株式会社ボナック | 人工単一ガイドrna及びその用途 |
JP2020198880A (ja) * | 2016-01-30 | 2020-12-17 | 株式会社ボナック | 人工単一ガイドrna及びその用途 |
AU2017213405B2 (en) * | 2016-01-30 | 2021-02-04 | Bonac Corporation | Artificial single guide RNA and use thereof |
WO2018143475A1 (ja) | 2017-02-06 | 2018-08-09 | 日産化学工業株式会社 | 一本鎖オリゴヌクレオチド |
WO2018155487A1 (ja) * | 2017-02-21 | 2018-08-30 | 株式会社ボナック | 核酸含有dpi用粉末製剤及びその用途 |
JP2020182461A (ja) * | 2018-02-09 | 2020-11-12 | 住友化学株式会社 | 核酸分子の製造方法 |
JPWO2019156020A1 (ja) * | 2018-02-09 | 2020-06-25 | 住友化学株式会社 | 核酸分子の製造方法 |
WO2019156020A1 (ja) * | 2018-02-09 | 2019-08-15 | 住友化学株式会社 | 核酸分子の製造方法 |
WO2019182037A1 (ja) | 2018-03-20 | 2019-09-26 | 国立大学法人東京工業大学 | 毒性が低減されたアンチセンスオリゴヌクレオチド |
Also Published As
Publication number | Publication date |
---|---|
RU2016130611A (ru) | 2018-01-31 |
SG10201913570XA (en) | 2020-03-30 |
JP6425142B2 (ja) | 2018-11-21 |
RU2016130611A3 (ja) | 2018-08-27 |
CN112646812A (zh) | 2021-04-13 |
EP3088525A4 (en) | 2017-08-09 |
JP2018145199A (ja) | 2018-09-20 |
BR112016014986A2 (ja) | 2018-01-23 |
EP3088525A1 (en) | 2016-11-02 |
SG10201805087VA (en) | 2018-07-30 |
JP6653889B2 (ja) | 2020-02-26 |
IL271715B (en) | 2022-03-01 |
MX2016008518A (es) | 2017-01-26 |
CN106068324B (zh) | 2020-12-29 |
KR20160121510A (ko) | 2016-10-19 |
AU2014370829A1 (en) | 2016-08-11 |
IL271715A (en) | 2020-02-27 |
CN106068324A (zh) | 2016-11-02 |
US20160319282A1 (en) | 2016-11-03 |
IL246395B (en) | 2020-01-30 |
IL246395A0 (en) | 2016-08-31 |
SG11201605247XA (en) | 2016-08-30 |
CA2935022A1 (en) | 2015-07-02 |
KR102357337B1 (ko) | 2022-01-28 |
AU2014370829B2 (en) | 2021-03-11 |
JPWO2015099187A1 (ja) | 2017-03-23 |
US10934542B2 (en) | 2021-03-02 |
RU2697094C2 (ru) | 2019-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6653889B2 (ja) | 遺伝子発現制御のための人工マッチ型miRNAおよびその用途 | |
JP6471176B2 (ja) | 遺伝子発現制御のための天然型miRNAおよびその用途 | |
KR101894702B1 (ko) | 함질소 지환식 골격을 갖는 일본쇄 핵산 분자 | |
WO2018182008A1 (ja) | 遺伝子発現制御機能を有する環状型核酸分子 | |
KR20130090792A (ko) | 유전자 발현 제어를 위한 일본쇄 핵산 분자 | |
WO2013077446A1 (ja) | 遺伝子発現制御のための一本鎖核酸分子 | |
JP2019077696A (ja) | 核酸分子を安定に含有する組成物 | |
JP2013055913A (ja) | 遺伝子発現制御のための一本鎖rna分子 | |
JP7204649B2 (ja) | 線維症治療剤 | |
JP2017012028A (ja) | 人工マッチ型miRNAおよびその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14874254 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 246395 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2015555078 Country of ref document: JP Kind code of ref document: A Ref document number: 2935022 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/008518 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15108453 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016014986 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20167020185 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2014874254 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014874254 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016130611 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014370829 Country of ref document: AU Date of ref document: 20141227 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016014986 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160624 |